<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 3.3b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: ecte_q2.xfr; Date: 2012/08/09T17:44:37 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:us-roles="http://fasb.org/us-roles/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:ecte="http://echotx.com/20120630">
    <link:schemaRef xlink:href="ecte-20120630.xsd" xlink:type="simple" />
    <xbrli:context id="From2012-01-01to2012-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-08-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-08-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-04-01to2011-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-04-01</xbrli:startDate>
        <xbrli:endDate>2011-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_ResearchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_DrugMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ecte:DrugMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_PharmaceuticalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ecte:PharmaceuticalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_PatentedTechnologyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_IntangibleassetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ecte:IntangibleassetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_FranklinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ecte:FranklinMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_PhiladelphiaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PartiesToContractualArrangementAxis">ecte:PhiladelphiaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_ManufacturinglaboratoryandofficespaceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ecte:ManufacturinglaboratoryandofficespaceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_CorporateofficespaceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ecte:CorporateofficespaceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_ManufacturinglaboratoryandofficespacemMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ecte:ManufacturinglaboratoryandofficespacemMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-05-31_CorporateofficespaceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ecte:CorporateofficespaceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-06-30_Plan2003Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecte:PlanNameAxis">ecte:Plan2003Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Plan2003Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecte:PlanNameAxis">ecte:Plan2003Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-06-30_Plan2008Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecte:PlanNameAxis">ecte:Plan2008Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Plan2008Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecte:PlanNameAxis">ecte:Plan2008Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-06-30_NotPursuanttoaPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecte:PlanNameAxis">ecte:NotPursuanttoaPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoplacementagentsinprivateplacement1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoplacementagentsinprivateplacement1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtofinancialinvestmentadvisor1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtofinancialinvestmentadvisor1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtofinancialadvisorinconnectionwithanacquisition1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtofinancialadvisorinconnectionwithanacquisition1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtofinancialinvestmentadvisor2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtofinancialinvestmentadvisor2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoinvestorsinprivateplacement1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoinvestorsinprivateplacement2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoinvestorsinprivateplacementofpreferredstock1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoinvestorsinprivateplacementofpreferredstock1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoinvestorsinprivateplacementofpreferredstock2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoinvestorsinprivateplacementofpreferredstock2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoinvestorsinprivateplacementofpreferredstock3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoinvestorsinprivateplacementofpreferredstock3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtovendor1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtovendor1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoinvestorsinprivateplacement3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtovendor2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtovendor2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoinvestorsinprivateplacement4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoinvestorsinprivateplacement5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoinvestorinprivateplacement6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoinvestorinprivateplacement6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement7Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoinvestorsinprivateplacement7Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement8Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoinvestorsinprivateplacement8Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoplacementagentinprivateplacement2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoplacementagentinprivateplacement3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement9Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoinvestorsinprivateplacement9Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement10Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoinvestorsinprivateplacement10Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement11Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoinvestorsinprivateplacement11Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement12Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoinvestorsinprivateplacement12Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoplacementagentinprivateplacement4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoplacementagentinprivateplacement5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement13Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoinvestorsinprivateplacement13Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement14Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoinvestorsinprivateplacement14Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoplacementagentinprivateplacement6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement7Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoplacementagentinprivateplacement7Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement15Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoinvestorsinprivateplacement15Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement16Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoinvestorsinprivateplacement16Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement8Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoplacementagentinprivateplacement8Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement9Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoplacementagentinprivateplacement9Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement17Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoinvestorsinprivateplacement17Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement18Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoinvestorsinprivateplacement18Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement19Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:Grantedtoinvestorsinprivateplacement19Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_TotaloutstandingwarrantsaccountedforasequityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:TotaloutstandingwarrantsaccountedforasequityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_WeightedaverageexercisepriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:WeightedaverageexercisepriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_WeightedaveragetimetoexpirationinyearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ecte:WeightedaveragetimetoexpirationinyearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-06-30_NonRevolvingDrawCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001031927</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ecte:CreditFacilityAxis">ecte:NonRevolvingDrawCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Percent">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Area">
      <xbrli:measure>ecte:sqft</xbrli:measure>
    </xbrli:unit>
    <dei:DocumentFiscalYearFocus contextRef="From2012-01-01to2012-06-30">2012</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2012-01-01to2012-06-30">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityFilerCategory contextRef="From2012-01-01to2012-06-30">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityCurrentReportingStatus contextRef="From2012-01-01to2012-06-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityVoluntaryFilers contextRef="From2012-01-01to2012-06-30">No</dei:EntityVoluntaryFilers>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2012-01-01to2012-06-30">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:CurrentFiscalYearEndDate contextRef="From2012-01-01to2012-06-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="From2012-01-01to2012-06-30">false</dei:AmendmentFlag>
    <dei:DocumentPeriodEndDate contextRef="From2012-01-01to2012-06-30">2012-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentType contextRef="From2012-01-01to2012-06-30">10-Q</dei:DocumentType>
    <dei:EntityCentralIndexKey contextRef="From2012-01-01to2012-06-30">0001031927</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="From2012-01-01to2012-06-30">Echo Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityPublicFloat contextRef="AsOf2012-08-07" unitRef="USD" decimals="0">39838</dei:EntityPublicFloat>
    <us-gaap:AssetsCurrent contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">3740766</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">9563511</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">218409</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">274208</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="AsOf2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">6667</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">3552</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">37065</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">407463</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">250000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">3111342</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">8995571</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2010-12-31" unitRef="USD" decimals="0">1342044</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2011-06-30" unitRef="USD" decimals="0">3199661</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:LeaseholdImprovementsGross contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">187264</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">187264</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:MachineryAndEquipmentGross contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">341620</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">156435</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">169581</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">186837</us-gaap:FurnitureAndFixturesGross>
    <ecte:OfficeAndLaboratoryEquipment contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">-689077</ecte:OfficeAndLaboratoryEquipment>
    <ecte:OfficeAndLaboratoryEquipment contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">-624817</ecte:OfficeAndLaboratoryEquipment>
    <ecte:ComputerEquipment contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">332287</ecte:ComputerEquipment>
    <ecte:ComputerEquipment contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">298290</ecte:ComputerEquipment>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">1719829</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">1453643</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">563597</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">317731</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">1156232</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">1135912</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Assets contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">13940179</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">19526807</us-gaap:Assets>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">9635816</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">9645565</us-gaap:AssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">10816</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">20565</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">9625000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">9625000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">1945313</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">2492463</us-gaap:LiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">742979</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">965832</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">392536</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">1035337</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">2405</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">2288</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">123721</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">123708</us-gaap:DeferredRevenueCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">683672</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">365298</us-gaap:AccountsPayableCurrent>
    <us-gaap:Liabilities contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">1947969</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">2558218</us-gaap:Liabilities>
    <us-gaap:DeferredRevenueNoncurrent contextRef="AsOf2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredRevenueNoncurrent contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">61867</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">2656</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">3888</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <ecte:SeriesD0.01ParValueAuthorized3600000SharesIssuedAndOutstanding3006000SharesAtMarch312012AndDecember312011PreferenceInLiquidationOf3006000AtMarch312012 contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">30060</ecte:SeriesD0.01ParValueAuthorized3600000SharesIssuedAndOutstanding3006000SharesAtMarch312012AndDecember312011PreferenceInLiquidationOf3006000AtMarch312012>
    <ecte:SeriesD0.01ParValueAuthorized3600000SharesIssuedAndOutstanding3006000SharesAtMarch312012AndDecember312011PreferenceInLiquidationOf3006000AtMarch312012 contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">30060</ecte:SeriesD0.01ParValueAuthorized3600000SharesIssuedAndOutstanding3006000SharesAtMarch312012AndDecember312011PreferenceInLiquidationOf3006000AtMarch312012>
    <ecte:SeriesC0.01ParValueAuthorized10000SharesIssuedAndOutstanding9974.185SharesAtMarch312012AndDecember312011 contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">100</ecte:SeriesC0.01ParValueAuthorized10000SharesIssuedAndOutstanding9974.185SharesAtMarch312012AndDecember312011>
    <ecte:SeriesC0.01ParValueAuthorized10000SharesIssuedAndOutstanding9974.185SharesAtMarch312012AndDecember312011 contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">100</ecte:SeriesC0.01ParValueAuthorized10000SharesIssuedAndOutstanding9974.185SharesAtMarch312012AndDecember312011>
    <us-gaap:CommonStockValue contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">396156</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">385442</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">99276015</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">98116327</us-gaap:AdditionalPaidInCapital>
    <ecte:CommonStockSubscribedForButNotPaidForOrIssued0And33333SharesAtMarch312012AndDecember312011Respectively contextRef="AsOf2012-06-30" unitRef="USD" xsi:nil="true" />
    <ecte:CommonStockSubscribedForButNotPaidForOrIssued0And33333SharesAtMarch312012AndDecember312011Respectively contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">6667</ecte:CommonStockSubscribedForButNotPaidForOrIssued0And33333SharesAtMarch312012AndDecember312011Respectively>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">13940179</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">19526807</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">11992210</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">16968589</us-gaap:StockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">-87710121</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">-81570007</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SalesRevenueNet contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">61854</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">388062</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">30927</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2011-04-01to2011-06-30" unitRef="USD" decimals="0">158520</us-gaap:SalesRevenueNet>
    <us-gaap:OtherSalesRevenueNet contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherSalesRevenueNet contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">145152</us-gaap:OtherSalesRevenueNet>
    <us-gaap:OtherSalesRevenueNet contextRef="From2012-04-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherSalesRevenueNet contextRef="From2011-04-01to2011-06-30" unitRef="USD" decimals="0">37065</us-gaap:OtherSalesRevenueNet>
    <us-gaap:LicensesRevenue contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">61854</us-gaap:LicensesRevenue>
    <us-gaap:LicensesRevenue contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">242910</us-gaap:LicensesRevenue>
    <us-gaap:LicensesRevenue contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">30927</us-gaap:LicensesRevenue>
    <us-gaap:LicensesRevenue contextRef="From2011-04-01to2011-06-30" unitRef="USD" decimals="0">121455</us-gaap:LicensesRevenue>
    <us-gaap:OperatingExpenses contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">6786208</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">3762364</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">3535159</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2011-04-01to2011-06-30" unitRef="USD" decimals="0">1974299</us-gaap:OperatingExpenses>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">3194256</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">1900265</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">1334852</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2011-04-01to2011-06-30" unitRef="USD" decimals="0">978150</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">3591952</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">1862099</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">2200307</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2011-04-01to2011-06-30" unitRef="USD" decimals="0">996149</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingIncomeLoss contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">-6724354</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">-3374302</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">-3504232</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2011-04-01to2011-06-30" unitRef="USD" decimals="0">-1815779</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">284</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">13354</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">134</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2011-04-01to2011-06-30" unitRef="USD" decimals="0">604</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">4515</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">3289</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">1556</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2011-04-01to2011-06-30" unitRef="USD" decimals="0">1210</us-gaap:InvestmentIncomeInterest>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">-1514</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2012-04-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2011-04-01to2011-06-30" unitRef="USD" xsi:nil="true" />
    <ecte:GainLossOnDisposalsOfAssets contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">21272</ecte:GainLossOnDisposalsOfAssets>
    <ecte:GainLossOnDisposalsOfAssets contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">-834</ecte:GainLossOnDisposalsOfAssets>
    <ecte:GainLossOnDisposalsOfAssets contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">21272</ecte:GainLossOnDisposalsOfAssets>
    <ecte:GainLossOnDisposalsOfAssets contextRef="From2011-04-01to2011-06-30" unitRef="USD" decimals="0">2531</ecte:GainLossOnDisposalsOfAssets>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">584240</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">-3162653</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">349888</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2011-04-01to2011-06-30" unitRef="USD" decimals="0">-123936</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:GainLossOnSaleOfDerivatives contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">601281</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:GainLossOnSaleOfDerivatives contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">-3151908</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:GainLossOnSaleOfDerivatives contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">369738</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:GainLossOnSaleOfDerivatives contextRef="From2011-04-01to2011-06-30" unitRef="USD" decimals="0">-122011</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:NetIncomeLoss contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">-6140114</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">-6536955</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">-3154344</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2011-04-01to2011-06-30" unitRef="USD" decimals="0">-1939715</us-gaap:NetIncomeLoss>
    <ecte:DeemedDividendOnBeneficialConversionFeatureOfSeriesDConvertiblePreferredStock contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <ecte:DeemedDividendOnBeneficialConversionFeatureOfSeriesDConvertiblePreferredStock contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">-1975211</ecte:DeemedDividendOnBeneficialConversionFeatureOfSeriesDConvertiblePreferredStock>
    <ecte:DeemedDividendOnBeneficialConversionFeatureOfSeriesDConvertiblePreferredStock contextRef="From2012-04-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <ecte:DeemedDividendOnBeneficialConversionFeatureOfSeriesDConvertiblePreferredStock contextRef="From2011-04-01to2011-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">93242</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="From2012-04-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="From2011-04-01to2011-06-30" unitRef="USD" decimals="0">47558</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">-6140114</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">-8605408</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">-3154344</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2011-04-01to2011-06-30" unitRef="USD" decimals="0">-1987273</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2012-01-01to2012-06-30" unitRef="USDPShares" decimals="INF">-0.16</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2011-01-01to2011-06-30" unitRef="USDPShares" decimals="INF">-0.26</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2012-04-01to2012-06-30" unitRef="USDPShares" decimals="INF">-0.08</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2011-04-01to2011-06-30" unitRef="USDPShares" decimals="INF">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
    <ecte:BasicAndDilutedWeightedAverageCommonSharesOutstanding contextRef="From2012-01-01to2012-06-30" unitRef="Shares" decimals="INF">38951809</ecte:BasicAndDilutedWeightedAverageCommonSharesOutstanding>
    <ecte:BasicAndDilutedWeightedAverageCommonSharesOutstanding contextRef="From2011-01-01to2011-06-30" unitRef="Shares" decimals="INF">33277823</ecte:BasicAndDilutedWeightedAverageCommonSharesOutstanding>
    <ecte:BasicAndDilutedWeightedAverageCommonSharesOutstanding contextRef="From2012-04-01to2012-06-30" unitRef="Shares" decimals="INF">39160643</ecte:BasicAndDilutedWeightedAverageCommonSharesOutstanding>
    <ecte:BasicAndDilutedWeightedAverageCommonSharesOutstanding contextRef="From2011-04-01to2011-06-30" unitRef="Shares" decimals="INF">33911459</ecte:BasicAndDilutedWeightedAverageCommonSharesOutstanding>
    <us-gaap:PaidInKindInterest contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaidInKindInterest contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">12159</us-gaap:PaidInKindInterest>
    <ecte:NoncashGainLossOnExtinguishmentOfDebt contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <ecte:NoncashGainLossOnExtinguishmentOfDebt contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">1514</ecte:NoncashGainLossOnExtinguishmentOfDebt>
    <ecte:FairValueOfCommonStockAndWarrantsIssuedForServices contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">50299</ecte:FairValueOfCommonStockAndWarrantsIssuedForServices>
    <ecte:FairValueOfCommonStockAndWarrantsIssuedForServices contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">380763</ecte:FairValueOfCommonStockAndWarrantsIssuedForServices>
    <us-gaap:ShareBasedCompensation contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">436056</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">286508</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">43757</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">14200</us-gaap:DepreciationDepletionAndAmortization>
    <ecte:NoncashLossOnDisposalOfAssets contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">21272</ecte:NoncashLossOnDisposalOfAssets>
    <ecte:NoncashLossOnDisposalOfAssets contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">2731</ecte:NoncashLossOnDisposalOfAssets>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">-5767283</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">-2602934</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">67147</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">207238</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">-61854</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">-242910</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">318374</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">-175345</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">9749</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">-10566</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">55799</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">-83602</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">33513</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">104423</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <ecte:StockSubscriptionsReceivable contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <ecte:StockSubscriptionsReceivable contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">285000</ecte:StockSubscriptionsReceivable>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">-468358</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">-377377</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">157463</us-gaap:IncreaseDecreaseInRestrictedCash>
    <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">128250</us-gaap:IncreaseDecreaseInRestrictedCash>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">310895</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">249127</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">1115</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">1009</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">6667</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">794761</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">151680</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">576224</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:RepaymentsOfShortTermDebt contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">75000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromShortTermDebt contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">1000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">2478702</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">351412</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">4837928</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">194180</us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">64250</us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">-5884229</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">1857617</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:InterestPaid contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">284</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">1196</us-gaap:InterestPaid>
    <ecte:IssuanceOfCommonStockInSettlementOfShortTermNote contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <ecte:IssuanceOfCommonStockInSettlementOfShortTermNote contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">25000</ecte:IssuanceOfCommonStockInSettlementOfShortTermNote>
    <ecte:DeemedDividendOnBeneficialConversionFeatureOfSeriesDConvertiblePreferredStock1 contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <ecte:DeemedDividendOnBeneficialConversionFeatureOfSeriesDConvertiblePreferredStock1 contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">1975211</ecte:DeemedDividendOnBeneficialConversionFeatureOfSeriesDConvertiblePreferredStock1>
    <ecte:ConversionOfNotesPayableAndAccruedInterestIntoSeriesDConvertiblePreferredStock contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <ecte:ConversionOfNotesPayableAndAccruedInterestIntoSeriesDConvertiblePreferredStock contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">1006000</ecte:ConversionOfNotesPayableAndAccruedInterestIntoSeriesDConvertiblePreferredStock>
    <ecte:FairValueOfWarrantsIssuedToInvestorRelationsServices contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <ecte:FairValueOfWarrantsIssuedToInvestorRelationsServices contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">173000</ecte:FairValueOfWarrantsIssuedToInvestorRelationsServices>
    <ecte:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">41520</ecte:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital>
    <ecte:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">2170727</ecte:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital>
    <ecte:FairValueOfWarrantsIssuedToFinancialAdvisorsAsFinancingCosts contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <ecte:FairValueOfWarrantsIssuedToFinancialAdvisorsAsFinancingCosts contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">41363</ecte:FairValueOfWarrantsIssuedToFinancialAdvisorsAsFinancingCosts>
    <ecte:FairValueOfCommonStockIssuedForShorttermNoteExtension contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <ecte:FairValueOfCommonStockIssuedForShorttermNoteExtension contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">10500</ecte:FairValueOfCommonStockIssuedForShorttermNoteExtension>
    <ecte:FairValueOfCommonStockIssuedToVendors contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">208000</ecte:FairValueOfCommonStockIssuedToVendors>
    <ecte:FairValueOfCommonStockIssuedToVendors contextRef="From2011-01-01to2011-06-30" unitRef="USD" xsi:nil="true" />
    <ecte:CancellationOfRestrictedCommonStock contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <ecte:CancellationOfRestrictedCommonStock contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">5250</ecte:CancellationOfRestrictedCommonStock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2012-01-01to2012-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;Echo&#13;Therapeutics, Inc. (the &amp;#147;Company&amp;#148;) is a transdermal medical device company with significant expertise in advanced skin&#13;permeation technology that is primarily focused on continuous glucose monitoring and needle-free drug delivery. The Company is&#13;developing its Prelude&amp;#174; SkinPrep System (&amp;#147;Prelude&amp;#148;) as a platform technology to allow for significantly enhanced&#13;and painless skin permeation that will enable two important applications:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;analyte&#13;                                                                                                          extraction, with the&#13;                                                                                                          Symphony&amp;#174; tCGM&#13;                                                                                                          System (&amp;#8220;Symphony&amp;#8221;)&#13;                                                                                                          for needle-free, continuous&#13;                                                                                                          glucose monitoring for&#13;                                                                                                          use in hospital critical&#13;                                                                                                          care units and for people&#13;                                                                                                          with diabetes; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;enhanced&#13;                                                                                                          needle-free drug delivery.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;The&#13;accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Sontra Medical,&#13;Inc., a Delaware corporation. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;The&#13;accompanying unaudited consolidated financial statements have been prepared in conformity with generally accepted accounting principles&#13;(&amp;#147;GAAP&amp;#148;) in the United States consistent with those applied in, and should be read in conjunction with, the Company&amp;#146;s&#13;audited consolidated financial statements and related footnotes for the year ended December 31, 2011 included in the Company&amp;#146;s&#13;Annual Report on Form 10-K as filed with the United States Securities and Exchange Commission (&amp;#147;SEC&amp;#148;) on March 15, 2012.&#13;These unaudited consolidated financial statements reflect all adjustments, consisting only of normal recurring adjustments, which&#13;are, in the opinion of management, necessary for a fair presentation of the Company&amp;#146;s financial position as of June 30, 2012&#13;and its results of operations and cash flows for the interim periods presented and are not necessarily indicative of results for&#13;subsequent interim periods or for the full year. The interim financial statements do not include all of the information and footnotes&#13;required by GAAP for complete financial statements and allowed by the relevant SEC rules and regulations; however, the Company&#13;believes that its disclosures are adequate to ensure that the information presented is not misleading. Certain amounts in prior&#13;periods have been reclassified to conform to current presentation.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2in"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;The&#13;accompanying consolidated financial statements have been prepared on a basis assuming that the Company is a going concern, which&#13;contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of June 30, 2012,&#13;the Company had cash of approximately $3,111,000, working capital of approximately $1,795,000 and an accumulated deficit of approximately&#13;$87,710,000. We will require additional capital to fund our product development, research, manufacturing and clinical programs&#13;in accordance with our current projected level of operations. The Company has funded its operations in the past primarily through&#13;debt and equity issuances. Management intends to pursue additional financing to fund its operations. Although management believes&#13;that it will be successful in securing additional financing, no assurances can be given as to the success of these plans or that&#13;such capital will be available to the Company in sufficient amounts to meet its operating cash needs or on terms acceptable to&#13;the Company. The consolidated financial statements do not include any adjustments that might result from the outcome of these&#13;uncertainties.&lt;/font&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="From2012-01-01to2012-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;As&#13;of June 30, 2012, the Company held approximately $3,100,000 in cash and cash equivalents. The Company&amp;#146;s cash equivalents&#13;consist solely of bank money market funds. From time to time, the Company may have cash balances in excess of federal insurance&#13;limits. The Company has never experienced any previous losses related to these balances. All of the Company&amp;#146;s non-interest&#13;bearing cash balances were fully insured at June 30, 2012 due to a temporary federal program in effect from December 31, 2010&#13;through December 31, 2012. Under the program, there is no limit on the amount of insurance for eligible accounts. Beginning in&#13;2013, insurance coverage will revert to $250,000 per depositor at each financial institution and non-interest bearing cash balances&#13;may again exceed federally insured limits.&lt;/font&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2012-01-01to2012-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;The&#13;Company&amp;#146;s intangible assets are related to the acquisition of assets from Durham Pharmaceuticals Ltd. in 2007 and are summarized&#13;as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: transparent"&gt;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;June 30, 2012&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31, 2011&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-weight: bold; text-align: left; padding-left: 2.35pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;Estimated&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;Accumulated&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: transparent"&gt;&#13;    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 2.35pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Life&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Cost&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;Amortization&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;Net&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;Net&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Contract related intangible asset:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="width: 35%; text-align: left; padding-bottom: 1pt; text-indent: -5.05pt; padding-left: 14.8pt"&gt;Cato Research discounted contract&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3 years&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;355,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;355,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Technology related intangible assets:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 14.8pt"&gt;Patents for the AzoneTS-based product candidates and formulation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6 years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,305,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,305,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,305,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 14.8pt"&gt;Drug Master Files containing formulation, clinical and safety documentation used by the FDA&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6 years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -5.05pt; padding-left: 14.05pt"&gt;In-process pharmaceutical products for 2 indications&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6 years&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,820,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,820,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,820,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -5.05pt; padding-left: 14.05pt"&gt;Total technology related intangible assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,625,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,625,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,625,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,980,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;355,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,625,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,625,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;Intangible&#13;assets related to technology are expected to be amortized on a straight-line basis over the period ending 2019, when the underlying&#13;patents expire, and will commence upon revenue generation which the Company estimates may occur as early as 2013. The contract&#13;related intangible asset was amortized over a three year period which ended in 2010.&lt;/font&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="From2012-01-01to2012-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;The&#13;Company leases approximately 13,000 square feet of manufacturing, laboratory and office space in a single facility located in&#13;Franklin, Massachusetts under a lease expiring March 31, 2014. Beginning June 1, 2012, a lease amendment increased the total space&#13;to 37,050 square feet and extended the expiration date to October 31, 2017.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2in"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;The&#13;Company also leases approximately 5,400 square feet of corporate office space in a single facility located in Philadelphia, Pennsylvania&#13;under a lease expiring April 30, 2014. Beginning June 1, 2012, a lease amendment increased the total space to 7,861 square feet&#13;and extended the expiration date to May 31, 2017.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2in"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;Future&#13;minimum lease payments for each of the next 5 years under these operating leases are as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Franklin&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Philadelphia&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;For the period ending December 31,&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;2012&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;209,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;90,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;299,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2013&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;424,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;183,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;607,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2014&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;434,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;187,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;621,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2015&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;444,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;192,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;636,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;454,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;196,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;650,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,965,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;848,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,813,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;The&#13;Company&amp;#146;s facilities lease expense was approximately $74,000 and $53,000 for the three months ended June 30, 2012 and 2011,&#13;respectively, and $151,000 and $86,000 for the six months ended June 30, 2012 and 2011, respectively.&lt;/font&gt;&lt;/p&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <ecte:DerivativeWarrantLiabilityTextBlock contextRef="From2012-01-01to2012-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;At&#13;June 30, 2012 and December 31, 2011, the Company had outstanding warrants to purchase 7,268,974 and 7,527,529 shares of its Common&#13;Stock, respectively. Included in these outstanding warrants at June 30, 2012 are warrants to purchase 516,587 shares that are&#13;considered to be derivative financial instruments because the warrant agreements contain &amp;#147;down round&amp;#148; provisions whereby&#13;the number of shares covered by the warrants is subject to change in the event of certain future dilutive stock issuances. The&#13;fair value of these derivative instruments at June 30, 2012 was approximately $393,000, is considered Level 3 under the fair value&#13;hierarchy on a recurring basis, and is included in Derivative Warrant Liability, a current liability, in the Consolidated Balance&#13;Sheet. Changes in fair value of the derivative financial instruments are recognized in the Consolidated Statement of Operations&#13;as a Derivative Warrant Liability Gain or Loss. The Derivative Warrant Liability Gain for the three and six months ended June&#13;30, 2012 was approximately $370,000 and $602,000, respectively. The Derivative Warrant Liability Loss for the three and six months&#13;ended June 30, 2011 was approximately $122,000 and $3,152,000, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2in"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;The&#13;derivative warrant liability represents the risk exposure pertaining to the warrants and is based on the fair value of the underlying&#13;common stock and the gain or loss on the derivative warrant liability is a result of the change in fair value of the underlying&#13;common stock. For the six months ended June 30, 2012, holders exercised warrants with &amp;#147;down round&amp;#148; provisions to purchase&#13;118,500 shares, which resulted in a reclassification of approximately $42,000 from the Derivative Warrant Liability to Additional&#13;Paid-in Capital. For the six months ended June 30, 2011, holders exercised warrants with &amp;#147;down round&amp;#148; provisions to&#13;purchase 602,693 shares, which resulted in a reclassification of approximately $2,171,000 from the Derivative Liability to Additional&#13;Paid-in Capital.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;The&#13;table below presents the changes in the derivative warrant liability for the six months ended June 30, 2012 and 2011:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2012&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2011&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 56%; text-align: left; text-indent: 4.5pt; padding-left: 6.65pt"&gt;Derivative warrant liability as of January 1&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,035,337&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,544,996&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: 22.5pt; padding-left: 6.65pt"&gt;&lt;font style="font-size: 10pt"&gt;Total unrealized losses included in net loss &lt;sup&gt;(1)&lt;/sup&gt;&amp;#9;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Courier New, Courier, Monospace; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace; text-align: right"&gt;2,191,147&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: 22.5pt; padding-left: 6.65pt"&gt;&lt;font style="font-size: 10pt"&gt;Total realized losses included in net loss &lt;sup&gt;(1)&lt;/sup&gt;&amp;#9;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Courier New, Courier, Monospace; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace; text-align: right"&gt;978,678&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: 22.5pt; padding-left: 6.65pt"&gt;&lt;font style="font-size: 10pt"&gt;Total unrealized gains included in net loss &lt;sup&gt;(1)&lt;/sup&gt;&amp;#9;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(539,648&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Courier New, Courier, Monospace; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace; text-align: right"&gt;(17,917&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: 22.5pt; padding-left: 6.65pt"&gt;&lt;font style="font-size: 10pt"&gt;Total realized gains included in net loss &lt;sup&gt;(1)&lt;/sup&gt;&amp;#9;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(61,633&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-family: Courier New, Courier, Monospace; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 33pt"&gt;Reclassification of derivative warrant liability to additional paid-in capital for derivative warrants exercised&amp;#9;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(41,520&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-family: Courier New, Courier, Monospace; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Courier New, Courier, Monospace; text-align: right"&gt;(2,170,726&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Courier New, Courier, Monospace; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: 4.5pt; padding-left: 6.65pt"&gt;Derivative warrant liability as of June 30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;392,536&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,526,178&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 6.65pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -13.7pt; padding-left: 24.5pt"&gt;&lt;font style="font-size: 10pt; line-height: 94%"&gt;(1)&lt;/font&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="line-height: 94%"&gt;Included in derivative warrant liability gain or loss in the Consolidated Statement of Operations.&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</ecte:DerivativeWarrantLiabilityTextBlock>
    <us-gaap:PreferredStockTextBlock contextRef="From2012-01-01to2012-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;The&#13;Company is authorized to issue up to 40,000,000 shares of preferred stock with such rights, preferences and privileges as are&#13;determined by the Board of Directors.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.2in; text-align: left; text-indent: -0.2in"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Series&#13;C Convertible Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.2in; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;The&#13;Company has authorized 10,000 shares of Series C Preferred Stock (the &amp;#147;Series C Stock&amp;#148;), of which 9,974.185 shares were&#13;issued and outstanding as of June 30, 2012 and December 31, 2011.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2in"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Series&#13;D Convertible Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;The&#13;Company has authorized 3,600,000 shares of Series D Preferred Stock (the &amp;#147;Series D Stock&amp;#148;), of which 3,006,000 shares&#13;were issued and outstanding as of June 30, 2012 and December 31, 2011.&lt;/font&gt;&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2012-01-01to2012-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;The&#13;Company has authorized 150,000,000 shares of Common Stock, of which 39,615,344 and 38,543,944 shares were issued and outstanding&#13;as of June 30, 2012 and December 31, 2011, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/94% Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 15pt"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock&#13;Issued in Exchange for Services &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;During&#13;the six months ended June 30, 2012 and 2011, the Company issued 28,666 and 100,000 shares, respectively, of Common Stock with&#13;a fair value of $50,299 and $339,000, respectively, to vendors in exchange for their services. Expenses associated with these&#13;transactions were included in Selling, General and Administrative Expenses in the Consolidated Statements of Operations.&lt;/font&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2012-01-01to2012-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;In&#13;March 2003, the Company&amp;#146;s shareholders approved its 2003 Stock Option and Incentive Plan (the &amp;#147;2003 Plan&amp;#148;). Pursuant&#13;to the 2003 Plan, the Company&amp;#146;s Board of Directors (or its committees and/or executive officers delegated by the Board of&#13;Directors) may grant incentive and nonqualified stock options, restricted stock, and other stock-based awards to the Company&amp;#146;s&#13;employees, officers, directors, consultants and advisors. As of June 30, 2012, the maximum aggregate number of shares that may&#13;be authorized for issuance under the 2003 Plan for all periods is 1,600,000 shares. As of June 30, 2012, there were 161,250 restricted&#13;shares of Common Stock issued and options to purchase an aggregate of 514,000 shares of Common Stock outstanding under the 2003&#13;Plan and 560,000 shares available for future grants.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;In&#13;May 2008, the Company&amp;#146;s shareholders approved the 2008 Equity Compensation Plan (the &amp;#147;2008 Plan&amp;#148;). The 2008 Plan&#13;provides for grants of incentive stock options to employees and nonqualified stock options and restricted stock to employees,&#13;consultants and non-employee directors of the Company. In July 2010, the Company&amp;#146;s shareholders approved an amendment to&#13;the &lt;font style="color: black"&gt;2008 Plan to increase the maximum number of shares of Common Stock available under the Plan by&#13;2,000,000 shares to 4,700,000 shares. In June 2012, the Company&amp;#146;s shareholders approved an amendment to the 2008 Plan to&#13;increase the maximum number of shares available under the Plan by 5,300,000 shares to 10,000,000 shares. &lt;/font&gt;As of June 30,&#13;2012, there were restricted shares of Common Stock issued and options to purchase an aggregate of 3,978,406 shares of Common Stock&#13;outstanding under the 2008 Plan and 5,891,594 shares available for future grants.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.2in; text-align: left; text-indent: -0.2in"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;Stock Option Plans&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2003 Plan&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2008 Plan&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="font-weight: bold; text-decoration: underline; text-align: justify; padding-left: 5.4pt"&gt;Shares Available For Issuance&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 46%; text-align: justify; text-indent: -7.9pt; padding-left: 7.9pt"&gt;Total reserved for stock options and restricted stock&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,600,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;10,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Net restricted stock issued net of cancellations&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(161,250&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,208,406&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Stock options granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,544,491&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,275,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Add back options cancelled before exercise&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;678,491&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;375,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Options cancelled by plan vote&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Remaining shares available for future grants&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;572,750&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,891,594&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;Not Pursuant to a Plan&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Total granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,544,491&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,275,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Less:&amp;#160; Restricted stock cancelled&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: justify; text-indent: 22.5pt; padding-left: 5.4pt"&gt;Options cancelled&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(678,491&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(375,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,383,334&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: 22.5pt; padding-left: 5.4pt"&gt;Options exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(352,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(130,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(666,666&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Net shares outstanding before restricted stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;514,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,770,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,050,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Net restricted stock issued net of cancellations&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;161,250&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,208,406&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;284,844&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Outstanding shares at March 31, 2012&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;675,250&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,978,406&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,334,844&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Share-Based&#13;Compensation &amp;#150; Options&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;For&#13;stock options issued and outstanding during the six months ended June 30, 2012 and 2011, the Company recorded additional paid-in&#13;capital and non-cash compensation expense of approximately $407,000 and $287,000, respectively, each net of estimated forfeitures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;The&#13;fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model with certain&#13;assumptions noted below. Expected volatilities are based on historical volatility of the Common Stock using historical periods&#13;consistent with the expected term of the options. The Company uses historical data, as well as subsequent events occurring prior&#13;to the issuance of the financial statements, to estimate option exercise and employee termination and forfeitures within the valuation&#13;model. The expected term of stock options granted under the Company&amp;#146;s stock plans is based on the average of the contractual&#13;term (generally 10 years) and the vesting period (generally 24 to 42 months). The risk-free rate is based on the yield of a U.S.&#13;Treasury security with a term consistent with the option.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;The&#13;assumptions used principally for stock options granted to employees and members of the Company&amp;#146;s Board of Directors in the&#13;six months ended June 30, 2012 and 2011 were as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2012&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2011&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.94% &amp;#151; 2.05%&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.43% &amp;#151; 3.47%&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Expected term&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.5 years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.0 &amp;#151; 6.5 years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 56%; text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Forfeiture rate (excluding fully vested stock options)&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;15&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0% &amp;#151; 15%&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;131% &amp;#151; 137%&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;140% &amp;#151; 142%&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;A&#13;summary of stock option activity as of and for the six months ended June 30, 2012 is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: bold 8pt/93% Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-size: 10pt"&gt;&lt;u&gt;Stock Options&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Term&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="width: 18%; text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Outstanding at January 1, 2012&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,395,103&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1.68&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right; padding-left: 2.35pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;430,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-left: 2.35pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(233,666&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.96&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-left: 2.35pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Forfeited or expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(257,437&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4.58&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 1pt; padding-left: 2.35pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Outstanding at June 30, 2012&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,334,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1.53&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 2.5pt; padding-left: 2.35pt"&gt;7.3 years&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,866,200&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Exercisable at June 30, 2012&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,112,830&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.91&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 2.5pt; padding-left: 2.35pt"&gt;6.1 years&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,861,033&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;The&#13;weighted-average grant-date fair value of stock options granted during the six months ended June 30, 2012 was $1.84 per share.&#13;Share-based compensation expense recognized in the six months ended June 30, 2012 and 2011 was approximately $407,000 and $287,000,&#13;respectively. As of June 30, 2012, there was approximately $2,537,000 of total unrecognized compensation expense related to non-vested&#13;share-based option compensation arrangements. With the exception of the unrecognized share-based compensation related to certain&#13;restricted stock grants to officers and employees that contain performance conditions related to United States Food and Drug Administration&#13;(&amp;#147;FDA&amp;#148;) approval for Symphony or the sale of substantially all of the stock or assets of the Company (see Restricted&#13;Stock section below), unrecognized compensation is expected to be recognized over the next four years.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2in"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Share-Based&#13;Compensation &amp;#150; Restricted Stock&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;During&#13;the six months ended June 30, 2012, the Company granted an aggregate of 703,656 restricted shares of Common Stock to certain officers,&#13;employees, directors and consultants of the Company. The grants were issued pursuant to the 2008 Plan. The grant date fair value&#13;of these restricted stock grants was approximately $1,369,000.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 12pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 12pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;A&#13;summary of the Company&amp;#146;s nonvested restricted stock activity as of and for the six months ended June 30, 2012, is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt; background-color: yellow"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Restricted Stock&amp;#9;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 8pt/94% Times New Roman, Times, Serif; margin: 1pt 0 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Grant-Date&lt;/b&gt;&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="width: 56%; text-align: left; padding-left: 2.35pt"&gt;Nonvested at January 1, 2012&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,819,594&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1.72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 2.35pt"&gt;Granted this period&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;703,656&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 2.35pt"&gt;Grants made in prior periods, now becoming restricted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;220,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 2.35pt"&gt;Vested&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(110,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 2.35pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 2.35pt"&gt;Nonvested at June 30, 2012&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,633,250&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1.78&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2in"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;Among&#13;the 2,633,250 shares of non-vested restricted stock, the various vesting criteria include the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; line-height: 115%; margin-top: 0; margin-bottom: 10pt"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 31.5pt"&gt;&lt;/td&gt;&lt;td style="width: 13.5pt"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 10pt; color: black"&gt;1,679,594&#13;                                                                                                          shares of restricted&#13;                                                                                                          stock vest upon the&#13;                                                                                                          FDA approval of Symphony&#13;                                                                                                          or the sale of the Company;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; line-height: 115%; margin-top: 0; margin-bottom: 10pt"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 31.5pt"&gt;&lt;/td&gt;&lt;td style="width: 13.5pt"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 10pt; color: black"&gt;220,000&#13;                                                                                                          shares of restricted&#13;                                                                                                          stock vest upon the&#13;                                                                                                          sale of the Company;&#13;                                                                                                          and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; line-height: 115%; margin-top: 0; margin-bottom: 10pt"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 31.5pt"&gt;&lt;/td&gt;&lt;td style="width: 13.5pt"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 10pt; color: black"&gt;733,656&#13;                                                                                                          shares of restricted&#13;                                                                                                          stock vest over one&#13;                                                                                                          to four years, at each&#13;                                                                                                          of the anniversary dates&#13;                                                                                                          of the grants.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;As&#13;of June 30, 2012, there was approximately $1,368,000 of total unrecognized compensation expense related to non-vested&#13;share-based restricted stock arrangements granted pursuant to the Company&amp;#146;s equity compensation plans that vest over&#13;time in the forseeable future. As of June 30, 2012, the Company cannot estimate the timing of completion of performance&#13;vesting requirements required by certain of these restricted stock grant arrangements. Compensation expense related to&#13;these restricted share grants will be recognized when the Company concludes that achievement of the performance vesting&#13;conditions is probable.&lt;/font&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <ecte:WarrantsTextBlock contextRef="From2012-01-01to2012-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;At&#13;June 30, 2012, the Company had the following outstanding warrants:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Exercise Price&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Date of Expiration&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;Outstanding warrants accounted for as derivative warrant liability:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 56%; text-align: left"&gt;Granted to investors and placement agent in private placement&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;112,148&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1.28&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;7/16/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to financial investment advisor&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;7/25/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to financial advisor in connection with an acquisition&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61,625&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;9/14/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to financial investment advisor&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/11/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;154,990&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/11/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;177,324&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3/24/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: 17.1pt"&gt;Total outstanding warrants accounted for as derivative warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;516,587&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1.18&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Weighted average time to expiration in years&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: center"&gt;0.48 years&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;Outstanding warrants accounted for as equity:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to investors in private placement of preferred stock&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,249&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;9/30/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to investors in private placement of preferred stock&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;198,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;10/28/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to investors in private placement of preferred stock&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;390,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/28/2014&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to vendor&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3/15/2014&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;400,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6/30/2014&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;768,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11/13/2014&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to placement agent in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;256,906&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11/13/2014&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to vendor&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;12/1/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;63,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;12/3/2014&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;341,325&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/9/2015&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to placement agents in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/9/2015&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to investor in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,375&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3/18/2015&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to financial investment advisor&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/10/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to financial investment advisor&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,367&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3/3/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;187,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11/5/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;187,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11/5/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to placement agent in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11/5/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to placement agent in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11/5/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11/26/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11/26/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;495,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;12/29/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;512,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;12/29/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to placement agent in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;12/29/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to placement agent in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;12/29/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;245,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1/4/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;245,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1/4/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to placement agent in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,125&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1/4/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to placement agent in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,125&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1/4/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;255,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/3/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;280,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/3/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to placement agent in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/3/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to placement agent in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/3/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/8/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/8/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;959,582&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12/7/2014&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: 12.05pt; padding-left: 5.05pt"&gt;Total outstanding warrants accounted for as equity&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,752,387&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Weighted average time to expiration in years&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: center"&gt;0.92 years&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 9pt; font-weight: bold; text-align: left; padding-left: 5.4pt"&gt;&lt;p style="font: 9pt/93% Times New Roman, Times, Serif; margin: 3pt 0 0 5.05pt; text-align: left; text-indent: -5.95pt"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 9pt/93% Times New Roman, Times, Serif; margin: 3pt 0 0 5.05pt; text-align: left; text-indent: -5.95pt"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Totals for all warrants outstanding:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: 12.05pt; padding-left: 5.05pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,268,974&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1.95&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Weighted average time to expiration in years&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: center"&gt;0.89 years&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;A&#13;summary of warrant activity for the six months ended June 30, 2012 is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 9pt; text-decoration: underline; text-align: justify; padding-bottom: 1pt; padding-left: 2.35pt"&gt;&lt;p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 9pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; text-align: right"&gt;&lt;p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&lt;u&gt;&amp;#9;Shares&amp;#9;&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 9pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: right"&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#9;Weighted-&lt;/b&gt;&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#9;Average&lt;/b&gt;&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&amp;#9;Exercise&lt;/b&gt;&lt;/font&gt;&lt;/p&gt; &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&lt;u&gt;&amp;#9;Price&amp;#9;&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="width: 56%; text-align: justify; padding-left: 2.35pt"&gt;Outstanding at January 1, 2012&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;7,527,529&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 2.35pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 2.35pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(118,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 1pt; padding-left: 2.35pt"&gt;Forfeited or expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(140,055&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1.07&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 2.35pt"&gt;Outstanding at June 30, 2012&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,268,974&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1.95&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Exercise&#13;of Common Stock Warrants&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;During&#13;the six months ended June 30, 2012, the Company issued 118,500 shares of Common Stock upon the exercise of warrants.&lt;/font&gt;&lt;/p&gt;</ecte:WarrantsTextBlock>
    <us-gaap:RevenueRecognitionServicesLicensingFees contextRef="From2012-01-01to2012-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;In&#13;2009, the Company entered into a License Agreement with Handok Pharmaceuticals Co., Ltd. (&amp;#147;Handok&amp;#148;) pursuant to which&#13;the Company granted Handok a license to develop, use, market, sell and import Symphony for continuous glucose monitoring for use&#13;by medical facilities and/or individual consumers in South Korea (the &amp;#147;Handok License&amp;#148;). The Handok License has a minimum&#13;term of 10 years from the date of the first commercial sale of Symphony in South Korea.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;The&#13;Company received a licensing fee of approximately $500,000 upon execution of the Handok License as well as future milestone payments&#13;and royalties. The Company recognizes the upfront, nonrefundable payments as revenue on a straight-line basis over the contractual&#13;or estimated performance period. During the six months ended June 30, 2012 and 2011, the Company recorded approximately $62,000&#13;and $243,000, respectively, of nonrefundable license revenue. As of June 30, 2012, approximately $124,000 of deferred revenue&#13;remains unrecognized, which is recognizable over the next 12 months and shown as Deferred Revenue amongst current liabilities&#13;on the Consolidated Balance Sheet.&lt;/font&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionServicesLicensingFees>
    <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="From2012-01-01to2012-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;Harry&#13;G. Mitchell, the former Chief Operating Officer of the Company, resigned from that position in June 2011. On August 25, 2011,&#13;Mr. Mitchell filed a complaint in the Norfolk County Superior Court in Massachusetts against the Company and its Chief Executive&#13;Officer, Patrick T. Mooney, claiming, among other things, that he resigned for good reason (as defined under his employment agreement)&#13;and was therefore entitled to certain benefits and also to certain payments under state wage payment statutes. Mr. Mitchell sought&#13;compensatory damages, an award of attorneys&amp;#146; fees and costs and other relief. The Company responded to the complaint by serving&#13;a partial motion to dismiss on September 28, 2011. The Company had accrued approximately $400,000 in settlement liability as of&#13;September 30, 2011 with respect to this matter, reflecting the Company&amp;#146;s best estimate then of probable loss exposure.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2in"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;On&#13;December 20, 2011, the Company and Dr. Mooney entered into a Settlement and Release Agreement (the &amp;#147;Settlement Agreement&amp;#148;)&#13;with Mr. Mitchell in order to enable the Company&amp;#146;s senior management team to focus its full attention on product development&#13;and business operations. In accordance with the Settlement Agreement, the Company agreed to (i) pay Mr. Mitchell a settlement&#13;payment in the gross amount of $125,000, to be paid in installments over a three month period, (ii) pay Mr. Mitchell&amp;#146;s full&#13;monthly COBRA premium for six months, and (iii) fully vest 100,000 shares of restricted Common Stock (the &amp;#147;Shares&amp;#148;)&#13;held by Mr. Mitchell. The Shares vested in January 2012, the date when the Company received confirmation of Mr. Mitchell&amp;#146;s&#13;dismissal of his lawsuit, and resulted in an outstanding settlement accrued liability relating to the settlement of $290,000,&#13;representing the then fair value of the Common Stock to be issued, in the Company&amp;#146;s consolidated balance sheet as of December&#13;31, 2011. As of June 30, 2012, this matter has been completely resolved.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;When&#13;the Shares were issued in January 2012, the accrued liability was largely satisfied and $82,000 of the previously recorded share-based&#13;compensation was reversed in that period due to a decline in the market value of the underlying Common Stock.&lt;/font&gt;&lt;/p&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2012-01-01to2012-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Financing Arrangement with Platinum-Montaur Life Sciences&#13;LLC&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 14pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 39pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39pt"&gt;On August 8, 2012,&#13;the Company and Platinum-Montaur Life Sciences LLC, a Delaware limited liability company (&amp;#147;Montaur&amp;#148;) signed a commitment&#13;letter (the &amp;#147;Commitment Letter&amp;#148;) pursuant to which Montaur agreed to make a non-revolving draw credit facility available&#13;to the Company in an initial aggregate principal amount of $5,000,000 (the &amp;#147;Draw Credit Maximum Amount&amp;#148;). The term&#13;of the credit facility will be five years from the date of closing (the &amp;#147;Maturity Date&amp;#148;). Pursuant to the terms of&#13;the Commitment Letter, the Company may make an aggregate principal amount of draws which do not exceed the Draw Credit Maximum&#13;Amount. The Company may not re-borrow the amount of any repaid draw. The Draw Credit Maximum Amount available pursuant to the Loan&#13;Agreement will increase in additional $3,000,000 increments, in an amount not to exceed $20,000,000, upon the occurrence of certain&#13;regulatory and clinical study milestones. The principal balance of each draw will bear interest from the applicable draw date at&#13;a rate equal to 10.0% per annum. Interest payable by the Company will compound monthly.&amp;#160;&amp;#160;The Company will make interest-only&#13;payments on the principal amount due in connection with each draw on the first business day of each month until the Maturity Date.&#13;The Company will have the right to permanently prepay any draw, in whole or in part.&lt;/p&gt;&#13;&#13;&lt;p style="font: 14pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39pt"&gt;On closing, the&#13;Company will issue Montaur a warrant to purchase 4,000,000 shares of Common Stock, with an exercise price of $2.00 per share and&#13;a term of five years.&amp;#160;&amp;#160;In addition, for each $1,000,000 draw, the Company will issue Montaur a warrant to purchase 1,000,000&#13;shares of Common Stock, with a term of five years and an exercise price equal to the lesser of: (a) 150% of the market price of&#13;the Common Stock at the time of the draw (but in no event less than $2.00 per share), or (b) $4.00 per share.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <ecte:SeriesCParValueMonetary contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">0.01</ecte:SeriesCParValueMonetary>
    <ecte:SeriesCParValueMonetary contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">0.01</ecte:SeriesCParValueMonetary>
    <ecte:SeriesCAuthorized contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">10000</ecte:SeriesCAuthorized>
    <ecte:SeriesCAuthorized contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">10000</ecte:SeriesCAuthorized>
    <ecte:SeriesCOutstanding contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">9974.185</ecte:SeriesCOutstanding>
    <ecte:SeriesCOutstanding contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">9974.185</ecte:SeriesCOutstanding>
    <ecte:SeriesCShareIssued contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">9974.185</ecte:SeriesCShareIssued>
    <ecte:SeriesCShareIssued contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">9974.185</ecte:SeriesCShareIssued>
    <ecte:SeriesDParValue contextRef="AsOf2012-06-30" unitRef="USDPShares" decimals="INF">0.01</ecte:SeriesDParValue>
    <ecte:SeriesDParValue contextRef="AsOf2011-12-31" unitRef="USDPShares" decimals="INF">0.01</ecte:SeriesDParValue>
    <ecte:SeriesDAuthorized contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">3600000</ecte:SeriesDAuthorized>
    <ecte:SeriesDAuthorized contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">3600000</ecte:SeriesDAuthorized>
    <ecte:SeriesDOutstanding contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">3006000</ecte:SeriesDOutstanding>
    <ecte:SeriesDOutstanding contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">3006000</ecte:SeriesDOutstanding>
    <ecte:SeriesDShareIssued contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">3006000</ecte:SeriesDShareIssued>
    <ecte:SeriesDShareIssued contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">3006000</ecte:SeriesDShareIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2012-06-30" unitRef="USDPShares" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2011-12-31" unitRef="USDPShares" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2012-06-30_Plan2003Member" unitRef="Shares" decimals="INF">1600000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2012-06-30_Plan2008Member" unitRef="Shares" decimals="INF">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">39615344</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">38543944</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">38543944</us-gaap:CommonStockSharesOutstanding>
    <ecte:ConvertiblePreferredStockseriesDpreferenceInLiquidation contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">3006000</ecte:ConvertiblePreferredStockseriesDpreferenceInLiquidation>
    <ecte:ConvertiblePreferredStockseriesDpreferenceInLiquidation contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">3006000</ecte:ConvertiblePreferredStockseriesDpreferenceInLiquidation>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2012-08-07" unitRef="Shares" decimals="INF">39838586</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2012-04-01to2012-06-30">&lt;p style="margin: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;Echo Therapeutics, Inc.&#13;(the &amp;#147;Company&amp;#148;) is atransdermal medical device company with significant expertise in advanced skin permeation technology&#13;that is primarily focused on continuous glucose monitoring and needle-free drug delivery. The Company is developing its Prelude&amp;#174;&#13;SkinPrep System (&amp;#147;Prelude&amp;#148;) as a platform technology to allow for significantly enhanced and painless skin permeation&#13;that will enable two important applications:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font-family: Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;analyte extraction, with the Symphony&amp;#174; tCGM System(&amp;#8220;Symphony&amp;#8221;) for needle-free,&#13;continuous glucose monitoring for use in hospital critical care units and for people with diabetes; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font-family: Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;enhanced needle-free drug delivery.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;The accompanying consolidated&#13;financial statements include the accounts of the Company and its wholly-owned subsidiary, Sontra Medical, Inc., a Delaware corporation.&#13;All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;The accompanying unaudited&#13;consolidated financial statements have been prepared in conformity with generally accepted accounting principles (&amp;#147;GAAP&amp;#148;)&#13;in the United States consistent with those applied in, and should be read in conjunction with, the Company&amp;#146;s audited consolidated&#13;financial statements and related footnotes for the year ended December 31, 2011 included in the Company&amp;#146;s Annual Report on&#13;Form 10-K as filed with the United States Securities and Exchange Commission (&amp;#147;SEC&amp;#148;) on March 15, 2012. These unaudited&#13;consolidated financial statements reflect all adjustments, consisting only of normal recurring adjustments, which are, in the opinion&#13;of management, necessary for a fair presentation of the Company&amp;#146;s financial position as of June 30, 2012 and its results&#13;of operations and cash flows for the interim periods presented and are not necessarily indicative of results for subsequent interim&#13;periods or for the full year. The interim financial statements do not include all of the information and footnotes required by&#13;GAAP for complete financial statements and allowed by the relevant SEC rules and regulations; however, the Company believes that&#13;its disclosures are adequate to ensure that the information presented is not misleading.Certain amounts in prior periods have been&#13;reclassified to conform to current presentation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2in"&gt;&amp;#160;The accompanying&#13;consolidated financial statements have been prepared on a basis assuming that the Company is a going concern, which contemplates&#13;the realization of assets and the satisfaction of liabilities in the normal course of business. As of June 30, 2012, the Company&#13;had cash of approximately $3,111,000, working capital of approximately $1,795,000 and an accumulated deficit of approximately&#13;$87,710,000. We will require additional capital to fund our product development, research, manufacturing and clinical programs&#13;in accordance with our current projected level of operations. The Company has funded its operations in the past primarily through&#13;debt and equity issuances. Management intends to pursue additional financing to fund its operations. Although management believes&#13;that it will be successful in securing additional financing, no assurances can be given as to the success of these plans or that&#13;such capital will be available to the Company in sufficient amounts to meet its operating cash needs or on terms acceptable to&#13;the Company. The consolidated financial statements do not include any adjustments that might result from the outcome of these&#13;uncertainties.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2012-04-01to2012-06-30">&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;The Company&amp;#146;s intangible assets are related to the&#13;acquisition of assets from Durham Pharmaceuticals Ltd. in 2007 and are summarized as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 8pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;June 30, 2012&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31, 2011&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 8pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: left"&gt;Estimated&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: left"&gt;Accumulated&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 8pt; font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: left; border-bottom: Black 1pt solid"&gt;Life&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: left; border-bottom: Black 1pt solid"&gt;Cost&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: left; border-bottom: Black 1pt solid"&gt;Amortization&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Net&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Net&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;Contract related intangible asset:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="width: 35%; text-align: left; padding-bottom: 1pt; text-indent: -5.05pt; padding-left: 14.8pt"&gt;Cato Research discounted contract&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;3 years&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;355,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;355,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Technology related intangible assets:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 14.8pt"&gt;Patents for the AzoneTS-based product candidates and formulation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6 years&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,305,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,305,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,305,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 14.8pt"&gt;Drug Master Files containing formulation, clinical and safety documentation used by the FDA&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6 years&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -5.05pt; padding-left: 14.05pt"&gt;In-process pharmaceuticalproducts for 2 indications&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6 years&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,820,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,820,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,820,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -5.05pt; padding-left: 14.05pt"&gt;Total technology related intangible assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,625,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,625,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,625,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,980,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;355,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,625,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,625,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2012-04-01to2012-06-30">&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;Future minimum lease payments for each of the next 5 years&#13;under these operating leases are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Franklin&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Philadelphia&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="text-align: justify"&gt;For the period ending December 31,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;2012&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;209,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;90,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;299,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2013&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;424,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;183,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;607,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2014&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;434,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;187,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;621,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2015&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;444,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;192,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;636,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;454,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;196,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;650,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,965,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;848,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,813,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="From2012-04-01to2012-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The table below presents the changes in the&#13;derivative warrant liability for the six months ended June 30, 2012 and 2011:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2012&lt;/td&gt;&lt;td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2011&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 56%; text-align: left; text-indent: 4.5pt; padding-left: 6.65pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Derivative&#13;    warrant liability as of January 1&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,035,337&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 8%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,544,996&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: 22.5pt; padding-left: 6.65pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    unrealized losses included in net loss &lt;sup&gt;(1)&lt;/sup&gt;&amp;#9;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Courier New, Courier, Monospace; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,191,147&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: 22.5pt; padding-left: 6.65pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    realized losses included in net loss &lt;sup&gt;(1)&lt;/sup&gt;&amp;#9;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Courier New, Courier, Monospace; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;978,678&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: 22.5pt; padding-left: 6.65pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    unrealized gains included in net loss &lt;sup&gt;(1)&lt;/sup&gt;&amp;#9;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(539,648&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Courier New, Courier, Monospace; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(17,917&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: 22.5pt; padding-left: 6.65pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&#13;    realized gains included in net loss &lt;sup&gt;(1)&lt;/sup&gt;&amp;#9;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(61,6333&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-family: Courier New, Courier, Monospace; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 33pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Reclassification&#13;    of derivative warrant liability to additional paid-in capital for derivative warrants exercised&amp;#9;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(41,520&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: Courier New, Courier, Monospace; padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font-family: Courier New, Courier, Monospace; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Courier New, Courier, Monospace; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2,170,726&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Courier New, Courier, Monospace; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: 4.5pt; padding-left: 6.65pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Derivative&#13;    warrant liability as of June 30&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;392,536&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,526,17&lt;/font&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2012-04-01to2012-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The assumptions used principally for stock&#13;options granted to employees and members of the Company&amp;#146;s Board of Directors in the six months ended June 30, 2012 and 2011&#13;were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 66%; padding-right: 2.35pt; padding-left: 2.35pt; text-align: left; font-size: 8pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-bottom: windowtext 1pt solid; padding-top: 1pt; padding-right: 2.35pt; padding-left: 2.35pt; text-align: center; font-size: 8pt; font-weight: bold"&gt;2012&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-top: 1pt; padding-right: 2.35pt; padding-left: 2.35pt; text-align: center; font-size: 8pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; border-bottom: windowtext 1pt solid; padding-top: 1pt; padding-right: 2.35pt; padding-left: 2.35pt; text-align: center; font-size: 8pt; font-weight: bold"&gt;2011&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 1pt; padding-right: 5.05pt; padding-left: 5.05pt; text-align: left; text-indent: -5.05pt"&gt;Risk-free interest rate&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 1pt; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;0.94% &amp;#151; 2.05%&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 1pt; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 1pt; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;2.43% &amp;#151; 3.47%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.05pt; padding-left: 5.05pt; text-align: left; text-indent: -5.05pt"&gt;Expected dividend yield&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 10.8pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#151;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 10.8pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 10.8pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.05pt; padding-left: 5.05pt; text-align: left; text-indent: -5.05pt"&gt;Expected term&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;6.5 years&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 10.8pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;6.0&amp;#151; 6.5 years&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.05pt; padding-left: 5.05pt; text-align: left; text-indent: -5.05pt"&gt;Forfeiture rate (excluding fully vested stock options)&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;15%&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;0% &amp;#151; 15%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 5.05pt; padding-left: 5.05pt; text-align: left; text-indent: -5.05pt"&gt;Expected volatility&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;131% &amp;#151; 137%&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;140% &amp;#151; 142%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt"&gt;A summary of stock option&#13;activity as of and for thesix months endedJune 30, 2012 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 54%; padding-right: 2.35pt; padding-left: 2.35pt"&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: bold 8pt/93% Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Stock Options&lt;/u&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 12%; border-bottom: windowtext 1pt solid; padding-right: 2.35pt; padding-left: 2.35pt"&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 2.35pt; padding-left: 2.35pt; text-align: center; font-size: 8pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; border-bottom: windowtext 1pt solid; padding-right: 2.35pt; padding-left: 2.35pt"&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 2.35pt; padding-left: 2.35pt; text-align: center; font-size: 8pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: windowtext 1pt solid; padding-right: 2.35pt; padding-left: 2.35pt"&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Contractual&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-right: 2.35pt; padding-left: 2.35pt; text-align: center; font-size: 8pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: windowtext 1pt solid; padding-right: 2.35pt; padding-left: 2.35pt"&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 3pt; padding-left: 5.05pt; text-align: left; text-indent: -5.05pt"&gt;Outstanding at January 1, 2012&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 3pt; padding-right: 2.35pt; padding-left: 2.35pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 3,395,103&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 3pt; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 3pt; padding-right: 2.35pt; padding-left: 2.35pt; text-align: left"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 1.68&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 3pt; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 3pt; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-top: 3pt; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-top: 3pt; padding-right: 2.35pt; padding-left: 2.35pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 2.35pt; padding-left: 5.05pt; text-align: left; text-indent: -5.05pt"&gt;Granted&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 430,000&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 1.84&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 2.35pt; padding-left: 5.05pt; text-align: left; text-indent: -5.05pt"&gt;Exercised&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; (233,666)&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 0.96&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 2.35pt; padding-left: 5.05pt; text-align: left; text-indent: -5.05pt"&gt;Forfeited or expired&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1pt solid; vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; (257,437)&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 4.58&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 2.35pt; padding-left: 5.05pt; text-align: left; text-indent: -5.05pt"&gt;Outstanding at June 30, 2012&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt double; vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 3,334,000&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt double; vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: left"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 1.53&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt double; vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;7.3 years&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt double; vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: justify"&gt;$ 1,866,200&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: bottom; padding-right: 2.35pt; padding-left: 5.05pt; text-align: left; text-indent: -5.05pt"&gt;Exercisable at June 30,2012&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt double; vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 2,112,830&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt double; vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: left"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; 0.91&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt double; vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;6.1 years&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; padding-right: 2.35pt; padding-left: 2.35pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: windowtext 1.5pt double; vertical-align: bottom; padding-right: 2.35pt; padding-left: 2.35pt; text-align: justify"&gt;$ 1,861,033&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="From2012-04-01to2012-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt"&gt;A summary of the Company&amp;#146;s&#13;nonvested restricted stock activity as of and for the six months ended June 30, 2012, is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 8pt; font-weight: bold; text-align: left; border-bottom: Black 1pt solid"&gt;Restricted Stock&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Shares&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted- &lt;br /&gt;Average &lt;br /&gt;Grant-Date &lt;br /&gt;Fair Value&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 56%; text-align: left; padding-left: 2.35pt"&gt;Nonvested at January 1, 2012&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,819,594&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1.72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 2.35pt"&gt;Granted this period&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;703,656&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 2.35pt"&gt;Grants made in prior periods, now becoming restricted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;220,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 2.35pt"&gt;Vested&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(110,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 2.35pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 2.35pt"&gt;Nonvested at June 30, 2012&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,633,250&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1.78&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2012-04-01to2012-06-30">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: justify; text-indent: 18pt"&gt;At June 30, 2012,&#13;the Company had the following outstanding warrants:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: justify; text-indent: 18pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 9pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of &lt;br /&gt;Shares &lt;br /&gt;Exercisable&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Exercise Price&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Date of Expiration&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;Outstanding warrants accounted for as derivative warrant liability:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 56%; text-align: left"&gt;Granted to investors and placement agent in private placement&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;112,148&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1.28&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;7/16/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to financial investment advisor&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;7/25/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to financial advisor in connection with an acquisition&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61,625&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;9/14/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to financial investment advisor&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/11/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;154,990&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/11/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;177,324&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3/24/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: 17.1pt"&gt;Total outstanding warrants accounted for as derivative warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;516,587&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1.18&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Weighted average time to expiration in years&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: center"&gt;0.48years&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;Outstanding warrants accounted for as equity:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to investors in private placement of preferred stock&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,249&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;9/30/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to investors in private placement of preferred stock&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;198,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;10/28/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to investors in private placement of preferred stock&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;390,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/28/2014&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to vendor&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3/15/2014&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;400,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6/30/2014&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;768,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11/13/2014&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to placement agent in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;256,906&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11/13/2014&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to vendor&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;12/1/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;63,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;12/3/2014&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;341,325&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/9/2015&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to placement agents in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/9/2015&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to investor in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,375&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3/18/2015&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Granted to financial investment advisor&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/10/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to financial investment advisor&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,367&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3/3/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;187,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11/5/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;187,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11/5/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to placement agent in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11/5/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to placement agent in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11/5/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11/26/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11/26/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;495,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;12/29/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;512,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;12/29/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to placement agent in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;12/29/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to placement agent in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;12/29/2012&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;245,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1/4/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;245,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1/4/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to placement agent in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,125&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1/4/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to placement agent in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,125&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1/4/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;255,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/3/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;280,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/3/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to placement agent in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/3/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to placement agent in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/3/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/8/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2/8/2013&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Granted to investors in private placement&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;959,582&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12/7/2014&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: 12.05pt; padding-left: 5.05pt"&gt;Total outstanding warrants accounted for as equity&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,752,387&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Weighted average time to expiration in years&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: center"&gt;0.92 years&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-weight: bold; text-align: left; padding-left: 5.4pt"&gt;&amp;#160;&lt;br /&gt;Totals for all warrants outstanding:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: 12.05pt; padding-left: 5.05pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,268,974&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1.95&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -5.05pt; padding-left: 5.05pt"&gt;Weighted average time to expiration in years&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: center"&gt;0.89 years&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;A summary of warrant activity&#13;for the six months ended June 30, 2012 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 8pt; font-weight: bold; text-align: justify; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;Warrants&lt;/u&gt;&amp;#9;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: justify; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;&amp;#9;Shares&amp;#9;&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: justify; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#9;Weighted-&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#9;Average&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#9;Exercise&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 8pt/93% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;&amp;#9;Price&amp;#9;&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="width: 56%; text-align: justify; padding-left: 2.35pt"&gt;Outstanding at January 1, 2012&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;7,527,529&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 2.35pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 2.35pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(118,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: right; padding-bottom: 1pt; padding-left: 2.35pt"&gt;Forfeited or expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(140,055&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1.07&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 2.35pt"&gt;Outstanding at June 30, 2012&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,268,974&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1.95&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:Cash contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">3111000</us-gaap:Cash>
    <ecte:WorkingCapital contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">1795000</ecte:WorkingCapital>
    <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">87710000</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
    <ecte:CashAndCashEquivalents1 contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">3100000</ecte:CashAndCashEquivalents1>
    <us-gaap:EstimatedInsuranceRecoveries contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">250000</us-gaap:EstimatedInsuranceRecoveries>
    <ecte:FiniteLivedIntangibleAssetUsefulLife3 contextRef="AsOf2012-06-30_ResearchMember">P3Y</ecte:FiniteLivedIntangibleAssetUsefulLife3>
    <ecte:FiniteLivedIntangibleAssetUsefulLife3 contextRef="AsOf2012-06-30_PatentsMember">P6Y</ecte:FiniteLivedIntangibleAssetUsefulLife3>
    <ecte:FiniteLivedIntangibleAssetUsefulLife3 contextRef="AsOf2012-06-30_DrugMember">P6Y</ecte:FiniteLivedIntangibleAssetUsefulLife3>
    <ecte:FiniteLivedIntangibleAssetUsefulLife3 contextRef="AsOf2012-06-30_PharmaceuticalMember">P6Y</ecte:FiniteLivedIntangibleAssetUsefulLife3>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">9980000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2012-06-30_ResearchMember" unitRef="USD" decimals="0">355000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2012-06-30_PatentsMember" unitRef="USD" decimals="0">1305000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2012-06-30_DrugMember" unitRef="USD" decimals="0">1500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2012-06-30_PharmaceuticalMember" unitRef="USD" decimals="0">6820000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2012-06-30_PatentedTechnologyMember" unitRef="USD" decimals="0">9625000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2012-06-30_IntangibleassetsMember" unitRef="USD" decimals="0">9980000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">355000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2012-06-30_ResearchMember" unitRef="USD" decimals="0">355000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2012-06-30_PatentsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2012-06-30_DrugMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2012-06-30_PharmaceuticalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2012-06-30_PatentedTechnologyMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2012-06-30_IntangibleassetsMember" unitRef="USD" decimals="0">355000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">9625000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">9625000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2012-06-30_ResearchMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2012-06-30_PatentsMember" unitRef="USD" decimals="0">1305000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2012-06-30_DrugMember" unitRef="USD" decimals="0">1500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2012-06-30_PharmaceuticalMember" unitRef="USD" decimals="0">6820000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2012-06-30_PatentedTechnologyMember" unitRef="USD" decimals="0">9625000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2012-06-30_IntangibleassetsMember" unitRef="USD" decimals="0">9625000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ecte:OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">299000</ecte:OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths>
    <ecte:OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths contextRef="AsOf2012-06-30_FranklinMember" unitRef="USD" decimals="0">209000</ecte:OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths>
    <ecte:OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths contextRef="AsOf2012-06-30_PhiladelphiaMember" unitRef="USD" decimals="0">90000</ecte:OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths>
    <ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">607000</ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo>
    <ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo contextRef="AsOf2012-06-30_FranklinMember" unitRef="USD" decimals="0">424000</ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo>
    <ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo contextRef="AsOf2012-06-30_PhiladelphiaMember" unitRef="USD" decimals="0">183000</ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo>
    <ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">621000</ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree>
    <ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree contextRef="AsOf2012-06-30_FranklinMember" unitRef="USD" decimals="0">434000</ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree>
    <ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree contextRef="AsOf2012-06-30_PhiladelphiaMember" unitRef="USD" decimals="0">187000</ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree>
    <ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">636000</ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour>
    <ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour contextRef="AsOf2012-06-30_FranklinMember" unitRef="USD" decimals="0">444000</ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour>
    <ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour contextRef="AsOf2012-06-30_PhiladelphiaMember" unitRef="USD" decimals="0">192000</ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour>
    <ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">650000</ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive>
    <ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive contextRef="AsOf2012-06-30_FranklinMember" unitRef="USD" decimals="0">454000</ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive>
    <ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive contextRef="AsOf2012-06-30_PhiladelphiaMember" unitRef="USD" decimals="0">196000</ecte:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">2813000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2012-06-30_FranklinMember" unitRef="USD" decimals="0">1965000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2012-06-30_PhiladelphiaMember" unitRef="USD" decimals="0">848000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <ecte:LeaseAmendment contextRef="AsOf2012-06-30_ManufacturinglaboratoryandofficespacemMember" unitRef="Area" decimals="INF">37050</ecte:LeaseAmendment>
    <ecte:LeaseAmendment contextRef="AsOf2017-05-31_CorporateofficespaceMember" unitRef="Area" decimals="INF">7861</ecte:LeaseAmendment>
    <ecte:DerivativeWarrants contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">392536</ecte:DerivativeWarrants>
    <ecte:DerivativeWarrants contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">1035337</ecte:DerivativeWarrants>
    <ecte:DerivativeWarrants contextRef="AsOf2010-12-31" unitRef="USD" decimals="0">1544996</ecte:DerivativeWarrants>
    <ecte:DerivativeWarrants contextRef="AsOf2011-06-30" unitRef="USD" decimals="0">2526178</ecte:DerivativeWarrants>
    <ecte:TotalUnrealizedLossesIncludedInNetLoss contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <ecte:TotalUnrealizedLossesIncludedInNetLoss contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">2191147</ecte:TotalUnrealizedLossesIncludedInNetLoss>
    <ecte:TotalRealizedLossesIncludedInNetLoss contextRef="From2012-01-01to2012-06-30" unitRef="USD" xsi:nil="true" />
    <ecte:TotalRealizedLossesIncludedInNetLoss contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">978678</ecte:TotalRealizedLossesIncludedInNetLoss>
    <ecte:TotalUnrealizedGainsIncludedInNetLoss contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">-539648</ecte:TotalUnrealizedGainsIncludedInNetLoss>
    <ecte:TotalUnrealizedGainsIncludedInNetLoss contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">-17917</ecte:TotalUnrealizedGainsIncludedInNetLoss>
    <ecte:TotalRealizedGainsIncludedInNetLoss contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">-61633</ecte:TotalRealizedGainsIncludedInNetLoss>
    <ecte:TotalRealizedGainsIncludedInNetLoss contextRef="From2011-01-01to2011-06-30" unitRef="USD" xsi:nil="true" />
    <ecte:ReclassificationOfDerivativeWarrantLiabilityToAdditionalPaidinCapitalForDerivativeWarrantsExercised contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">-41520</ecte:ReclassificationOfDerivativeWarrantLiabilityToAdditionalPaidinCapitalForDerivativeWarrantsExercised>
    <ecte:ReclassificationOfDerivativeWarrantLiabilityToAdditionalPaidinCapitalForDerivativeWarrantsExercised contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">-2170726</ecte:ReclassificationOfDerivativeWarrantLiabilityToAdditionalPaidinCapitalForDerivativeWarrantsExercised>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">7268974</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">7527529</us-gaap:WarrantsAndRightsOutstanding>
    <ecte:DerivativeFinancialInstruments contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">516587</ecte:DerivativeFinancialInstruments>
    <us-gaap:DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">393000</us-gaap:DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">602000</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">370000</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeLossOnDerivative contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">3152000</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:DerivativeLossOnDerivative contextRef="From2011-04-01to2011-06-30" unitRef="USD" decimals="0">122000</us-gaap:DerivativeLossOnDerivative>
    <ecte:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2012-01-01to2012-06-30" unitRef="Shares" decimals="INF">0.96</ecte:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <ecte:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2011-01-01to2011-06-30" unitRef="Shares" decimals="INF">602693</ecte:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">42000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">2171000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">40000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2012-06-30_SeriesCPreferredStockMember" unitRef="Shares" decimals="INF">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2011-12-31_SeriesCPreferredStockMember" unitRef="Shares" decimals="INF">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2012-06-30_SeriesDPreferredStockMember" unitRef="Shares" decimals="INF">3600000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2011-12-31_SeriesDPreferredStockMember" unitRef="Shares" decimals="INF">3600000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2012-06-30_SeriesCPreferredStockMember" unitRef="Shares" decimals="INF">9974.185</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2011-12-31_SeriesCPreferredStockMember" unitRef="Shares" decimals="INF">9974.185</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2012-06-30_SeriesDPreferredStockMember" unitRef="Shares" decimals="INF">3006000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2011-12-31_SeriesDPreferredStockMember" unitRef="Shares" decimals="INF">3006000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">1369000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2012-01-01to2012-06-30_Plan2003Member" unitRef="USD" decimals="0">1600000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2012-01-01to2012-06-30_Plan2008Member" unitRef="USD" decimals="0">10000000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures contextRef="From2012-01-01to2012-06-30_Plan2003Member" unitRef="USD" decimals="0">-161250</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures contextRef="From2012-01-01to2012-06-30_Plan2008Member" unitRef="USD" decimals="0">-2208406</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2012-01-01to2012-06-30_Plan2003Member" unitRef="Shares" decimals="INF">-1544491</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2012-01-01to2012-06-30_Plan2008Member" unitRef="Shares" decimals="INF">-2275000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2012-01-01to2012-06-30" unitRef="Shares" decimals="INF">-4257437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2012-01-01to2012-06-30_Plan2003Member" unitRef="Shares" decimals="INF">678491</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2012-01-01to2012-06-30_Plan2008Member" unitRef="Shares" decimals="INF">375000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <ecte:OptionsCancelledByPlanVote contextRef="From2012-01-01to2012-06-30_Plan2003Member" unitRef="Shares" xsi:nil="true" />
    <ecte:OptionsCancelledByPlanVote contextRef="From2012-01-01to2012-06-30_Plan2008Member" unitRef="Shares" xsi:nil="true" />
    <ecte:RemainingSharesAvailableForFutureGrants contextRef="From2012-01-01to2012-06-30_Plan2003Member" unitRef="Shares" decimals="INF">572750</ecte:RemainingSharesAvailableForFutureGrants>
    <ecte:RemainingSharesAvailableForFutureGrants contextRef="From2012-01-01to2012-06-30_Plan2008Member" unitRef="Shares" decimals="INF">5891594</ecte:RemainingSharesAvailableForFutureGrants>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross contextRef="From2012-01-01to2012-06-30_Plan2003Member" unitRef="USD" decimals="0">1544491</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross contextRef="From2012-01-01to2012-06-30_Plan2008Member" unitRef="USD" decimals="0">2275000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross contextRef="From2012-01-01to2012-06-30_NotPursuanttoaPlanMember" unitRef="USD" decimals="0">3100000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="From2012-01-01to2012-06-30_Plan2003Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="From2012-01-01to2012-06-30_Plan2008Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="From2012-01-01to2012-06-30_NotPursuanttoaPlanMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited contextRef="From2012-01-01to2012-06-30_Plan2003Member" unitRef="USD" decimals="0">-678491</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited contextRef="From2012-01-01to2012-06-30_Plan2008Member" unitRef="USD" decimals="0">-375000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited contextRef="From2012-01-01to2012-06-30_NotPursuanttoaPlanMember" unitRef="USD" decimals="0">-1383334</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2012-01-01to2012-06-30" unitRef="Shares" decimals="INF">-233666</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2012-01-01to2012-06-30_Plan2003Member" unitRef="Shares" decimals="INF">-352000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2012-01-01to2012-06-30_Plan2008Member" unitRef="Shares" decimals="INF">-130000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2012-01-01to2012-06-30_NotPursuanttoaPlanMember" unitRef="Shares" decimals="INF">-666666</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <ecte:NetSharesOutstandingBeforeRestrictedStock contextRef="From2012-01-01to2012-06-30_Plan2003Member" unitRef="Shares" decimals="INF">514000</ecte:NetSharesOutstandingBeforeRestrictedStock>
    <ecte:NetSharesOutstandingBeforeRestrictedStock contextRef="From2012-01-01to2012-06-30_Plan2008Member" unitRef="Shares" decimals="INF">1770000</ecte:NetSharesOutstandingBeforeRestrictedStock>
    <ecte:NetSharesOutstandingBeforeRestrictedStock contextRef="From2012-01-01to2012-06-30_NotPursuanttoaPlanMember" unitRef="Shares" decimals="INF">1050000</ecte:NetSharesOutstandingBeforeRestrictedStock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited contextRef="From2012-01-01to2012-06-30_Plan2003Member" unitRef="Shares" decimals="INF">161250</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited contextRef="From2012-01-01to2012-06-30_Plan2008Member" unitRef="Shares" decimals="INF">2208406</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited contextRef="From2012-01-01to2012-06-30_NotPursuanttoaPlanMember" unitRef="Shares" decimals="INF">284844</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2012-01-01to2012-06-30" unitRef="Percent" decimals="INF">0.0094</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2011-01-01to2011-06-30" unitRef="Percent" decimals="INF">0.0243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2012-01-01to2012-06-30" unitRef="Percent" decimals="INF">0.0205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2011-01-01to2011-06-30" unitRef="Percent" decimals="INF">0.0347</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeiturerateMinimum contextRef="From2011-01-01to2011-06-30" unitRef="Percent" decimals="INF">0</ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeiturerateMinimum>
    <ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeiturerateMaximum contextRef="From2012-01-01to2012-06-30" unitRef="Percent" decimals="INF">0.15</ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeiturerateMaximum>
    <ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeiturerateMaximum contextRef="From2011-01-01to2011-06-30" unitRef="Percent" decimals="INF">0.15</ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeiturerateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2012-01-01to2012-06-30" unitRef="Percent" decimals="INF">1.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2011-01-01to2011-06-30" unitRef="Percent" decimals="INF">1.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2012-01-01to2012-06-30" unitRef="Percent" decimals="INF">1.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2011-01-01to2011-06-30" unitRef="Percent" decimals="INF">1.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">3334000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">3395103</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2012-01-01to2012-06-30" unitRef="Shares" decimals="INF">430000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">2112830</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2012-06-30" unitRef="USDPShares" decimals="INF">1.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2011-12-31" unitRef="USDPShares" decimals="INF">1.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2012-06-30" unitRef="USDPShares" decimals="INF">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">1866200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">1861033</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">2633250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">1819594</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2012-01-01to2012-06-30" unitRef="Shares" decimals="INF">703656</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease contextRef="From2012-01-01to2012-06-30" unitRef="Shares" decimals="INF">220000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2012-01-01to2012-06-30" unitRef="Shares" decimals="INF">-110000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="From2012-01-01to2012-06-30" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2012-06-30" unitRef="USDPShares" decimals="INF">1.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2011-12-31" unitRef="USDPShares" decimals="INF">1.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2012-01-01to2012-06-30" unitRef="USDPShares" decimals="INF">1.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="From2012-01-01to2012-06-30" unitRef="USDPShares" decimals="INF">2.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <ecte:RestrictedSharesOfCommonStockIssuedAndOptionsToPurchaseAggregate contextRef="AsOf2012-06-30_Plan2003Member" unitRef="Shares" decimals="INF">161250</ecte:RestrictedSharesOfCommonStockIssuedAndOptionsToPurchaseAggregate>
    <ecte:RestrictedSharesOfCommonStockIssuedAndOptionsToPurchaseAggregate contextRef="AsOf2012-06-30_Plan2008Member" unitRef="Shares" decimals="INF">3978406</ecte:RestrictedSharesOfCommonStockIssuedAndOptionsToPurchaseAggregate>
    <ecte:StockGrantedDuringPeriodSharesSharebasedCompensation1 contextRef="AsOf2012-06-30_Plan2003Member" unitRef="Shares" decimals="INF">560000</ecte:StockGrantedDuringPeriodSharesSharebasedCompensation1>
    <ecte:StockGrantedDuringPeriodSharesSharebasedCompensation1 contextRef="AsOf2012-06-30_Plan2008Member" unitRef="Shares" decimals="INF">5891594</ecte:StockGrantedDuringPeriodSharesSharebasedCompensation1>
    <ecte:AdditionalPaidinCapitalAndNoncashCompensationExpense contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">407000</ecte:AdditionalPaidinCapitalAndNoncashCompensationExpense>
    <ecte:AdditionalPaidinCapitalAndNoncashCompensationExpense contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">287000</ecte:AdditionalPaidinCapitalAndNoncashCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2012-01-01to2012-06-30" unitRef="USDPShares" decimals="INF">1.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">407000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">287000</us-gaap:AllocatedShareBasedCompensationExpense>
    <ecte:TotalUnrecognizedCompensationExpense contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">2537000</ecte:TotalUnrecognizedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2012-01-01to2012-06-30" unitRef="Shares" decimals="INF">703656</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <ecte:OutstandingNonVestedRestrictedStockGrants contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">2643250</ecte:OutstandingNonVestedRestrictedStockGrants>
    <ecte:TotalUnrecognizedCompensationExpense1 contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">1378000</ecte:TotalUnrecognizedCompensationExpense1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-06-30_Grantedtoplacementagentsinprivateplacement1Member" unitRef="Shares" decimals="INF">112148</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-06-30_Grantedtofinancialinvestmentadvisor1Member" unitRef="Shares" decimals="INF">3000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-06-30_Grantedtofinancialadvisorinconnectionwithanacquisition1Member" unitRef="Shares" decimals="INF">61625</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-06-30_Grantedtofinancialinvestmentadvisor2Member" unitRef="Shares" decimals="INF">7500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement1Member" unitRef="Shares" decimals="INF">154990</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement2Member" unitRef="Shares" decimals="INF">177324</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2012-06-30_Grantedtoplacementagentsinprivateplacement1Member" unitRef="USDPShares" decimals="INF">1.28</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2012-06-30_Grantedtofinancialinvestmentadvisor1Member" unitRef="USDPShares" decimals="INF">1.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2012-06-30_Grantedtofinancialadvisorinconnectionwithanacquisition1Member" unitRef="USDPShares" decimals="INF">1.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2012-06-30_Grantedtofinancialinvestmentadvisor2Member" unitRef="USDPShares" decimals="INF">1.3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement1Member" unitRef="USDPShares" decimals="INF">0.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement2Member" unitRef="USDPShares" decimals="INF">1.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <ecte:DateOfExpirationRangeStart contextRef="AsOf2012-06-30_Grantedtoplacementagentsinprivateplacement1Member">2012-06-15</ecte:DateOfExpirationRangeStart>
    <ecte:DateOfExpiration contextRef="AsOf2012-06-30_Grantedtoplacementagentsinprivateplacement1Member">2012-07-16</ecte:DateOfExpiration>
    <ecte:DateOfExpiration contextRef="AsOf2012-06-30_Grantedtofinancialinvestmentadvisor1Member">2012-07-25</ecte:DateOfExpiration>
    <ecte:DateOfExpiration contextRef="AsOf2012-06-30_Grantedtofinancialadvisorinconnectionwithanacquisition1Member">2012-09-14</ecte:DateOfExpiration>
    <ecte:DateOfExpiration contextRef="AsOf2012-06-30_Grantedtofinancialinvestmentadvisor2Member">2013-11-02</ecte:DateOfExpiration>
    <ecte:DateOfExpiration contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement1Member">2013-11-02</ecte:DateOfExpiration>
    <ecte:DateOfExpiration contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement2Member">2013-03-24</ecte:DateOfExpiration>
    <ecte:TotalOutstandingWarrantsAccountedForAsDerivativeWarrantLiability contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">516587</ecte:TotalOutstandingWarrantsAccountedForAsDerivativeWarrantLiability>
    <ecte:WeightedAverageExercisePrice1 contextRef="AsOf2012-06-30" unitRef="USDPShares" decimals="INF">1.18</ecte:WeightedAverageExercisePrice1>
    <ecte:WeightedAverageTimeToExpirationInYears contextRef="AsOf2012-06-30">P5M23D</ecte:WeightedAverageTimeToExpirationInYears>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoplacementagentsinprivateplacement1Member" unitRef="Shares" decimals="INF">28500</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtofinancialinvestmentadvisor1Member" unitRef="Shares" decimals="INF">100000</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtofinancialinvestmentadvisor2Member" unitRef="Shares" decimals="INF">10367</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement1Member" unitRef="Shares" decimals="INF">400000</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement2Member" unitRef="Shares" decimals="INF">768000</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacementofpreferredstock1Member" unitRef="Shares" decimals="INF">32249</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacementofpreferredstock2Member" unitRef="Shares" decimals="INF">198333</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacementofpreferredstock3Member" unitRef="Shares" decimals="INF">390000</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtovendor1Member" unitRef="Shares" decimals="INF">60000</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement3Member" unitRef="Shares" decimals="INF">256906</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtovendor2Member" unitRef="Shares" decimals="INF">50000</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement4Member" unitRef="Shares" decimals="INF">63000</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement5Member" unitRef="Shares" decimals="INF">341325</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorinprivateplacement6Member" unitRef="Shares" decimals="INF">6375</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement7Member" unitRef="Shares" decimals="INF">187500</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement8Member" unitRef="Shares" decimals="INF">187500</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement2Member" unitRef="Shares" decimals="INF">5000</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement3Member" unitRef="Shares" decimals="INF">5000</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement9Member" unitRef="Shares" decimals="INF">35000</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement10Member" unitRef="Shares" decimals="INF">35000</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement11Member" unitRef="Shares" decimals="INF">495000</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement12Member" unitRef="Shares" decimals="INF">512500</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement4Member" unitRef="Shares" decimals="INF">30000</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement5Member" unitRef="Shares" decimals="INF">30000</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement13Member" unitRef="Shares" decimals="INF">245750</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement14Member" unitRef="Shares" decimals="INF">245750</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement6Member" unitRef="Shares" decimals="INF">18125</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement7Member" unitRef="Shares" decimals="INF">18125</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement15Member" unitRef="Shares" decimals="INF">255000</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement16Member" unitRef="Shares" decimals="INF">280000</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement8Member" unitRef="Shares" decimals="INF">1250</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement9Member" unitRef="Shares" decimals="INF">1250</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement17Member" unitRef="Shares" decimals="INF">250000</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement18Member" unitRef="Shares" decimals="INF">250000</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement19Member" unitRef="Shares" decimals="INF">959582</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1 contextRef="AsOf2012-06-30_TotaloutstandingwarrantsaccountedforasequityMember" unitRef="Shares" decimals="INF">6752387</ecte:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoplacementagentsinprivateplacement1Member" unitRef="USDPShares" decimals="INF">2.25</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtofinancialinvestmentadvisor1Member" unitRef="USDPShares" decimals="INF">1.5</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtofinancialinvestmentadvisor2Member" unitRef="USDPShares" decimals="INF">2</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement1Member" unitRef="USDPShares" decimals="INF">1.59</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement2Member" unitRef="USDPShares" decimals="INF">2</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacementofpreferredstock1Member" unitRef="USDPShares" decimals="INF">1</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacementofpreferredstock2Member" unitRef="USDPShares" decimals="INF">1.5</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacementofpreferredstock3Member" unitRef="USDPShares" decimals="INF">0.75</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtovendor1Member" unitRef="USDPShares" decimals="INF">0.6</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement3Member" unitRef="USDPShares" decimals="INF">1.5</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtovendor2Member" unitRef="USDPShares" decimals="INF">2</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement4Member" unitRef="USDPShares" decimals="INF">2</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement5Member" unitRef="USDPShares" decimals="INF">2.25</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorinprivateplacement6Member" unitRef="USDPShares" decimals="INF">2.25</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement7Member" unitRef="USDPShares" decimals="INF">1.5</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement8Member" unitRef="USDPShares" decimals="INF">2.5</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement2Member" unitRef="USDPShares" decimals="INF">1.5</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement3Member" unitRef="USDPShares" decimals="INF">2.5</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement9Member" unitRef="USDPShares" decimals="INF">1.5</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement10Member" unitRef="USDPShares" decimals="INF">2.5</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement11Member" unitRef="USDPShares" decimals="INF">1.5</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement12Member" unitRef="USDPShares" decimals="INF">2.5</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement4Member" unitRef="USDPShares" decimals="INF">1.5</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement5Member" unitRef="USDPShares" decimals="INF">2.5</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement13Member" unitRef="USDPShares" decimals="INF">1.5</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement14Member" unitRef="USDPShares" decimals="INF">2.5</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement6Member" unitRef="USDPShares" decimals="INF">1.5</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement7Member" unitRef="USDPShares" decimals="INF">2.5</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement15Member" unitRef="USDPShares" decimals="INF">1.5</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement16Member" unitRef="USDPShares" decimals="INF">2.5</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement8Member" unitRef="USDPShares" decimals="INF">1.5</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement9Member" unitRef="USDPShares" decimals="INF">2.5</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement17Member" unitRef="USDPShares" decimals="INF">1.5</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement18Member" unitRef="USDPShares" decimals="INF">2.5</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement19Member" unitRef="USDPShares" decimals="INF">3</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-06-30_WeightedaverageexercisepriceMember" unitRef="USDPShares" decimals="INF">2</ecte:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ecte:TotalWarrantsOutstanding contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">7268974</ecte:TotalWarrantsOutstanding>
    <ecte:TotalWeightedAverageExercisePrice1 contextRef="AsOf2012-06-30" unitRef="USDPShares" decimals="INF">1.95</ecte:TotalWeightedAverageExercisePrice1>
    <ecte:TotalweightedAverageTimeToExpirationInYears1 contextRef="AsOf2012-06-30">P10M20D</ecte:TotalweightedAverageTimeToExpirationInYears1>
    <ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber1 contextRef="AsOf2011-12-31" unitRef="Shares" decimals="INF">7527529</ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber1>
    <ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted1 contextRef="From2012-01-01to2012-06-30" unitRef="Shares" xsi:nil="true" />
    <ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2012-01-01to2012-06-30" unitRef="Shares" decimals="INF">-118500</ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures contextRef="From2012-01-01to2012-06-30" unitRef="Shares" decimals="INF">-140055</ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">7268974</ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1 contextRef="AsOf2012-06-30" unitRef="USDPShares" decimals="INF">1.95</ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1>
    <ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1 contextRef="AsOf2011-12-31" unitRef="USDPShares" decimals="INF">1.92</ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1>
    <ecte:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice1 contextRef="From2012-01-01to2012-06-30" unitRef="Shares" xsi:nil="true" />
    <ecte:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1 contextRef="From2012-01-01to2012-06-30" unitRef="Shares" decimals="INF">1.28</ecte:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice1>
    <ecte:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1 contextRef="From2012-01-01to2012-06-30" unitRef="Shares" decimals="INF">1.07</ecte:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice1>
    <us-gaap:LicenseAndServicesRevenue contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">500000</us-gaap:LicenseAndServicesRevenue>
    <ecte:NonRefundableLicenseRevenue1 contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">62000</ecte:NonRefundableLicenseRevenue1>
    <ecte:NonRefundableLicenseRevenue1 contextRef="From2011-04-01to2011-06-30" unitRef="USD" decimals="0">43000</ecte:NonRefundableLicenseRevenue1>
    <ecte:DeferredRevenueUnrecognized contextRef="AsOf2012-06-30" unitRef="USD" decimals="0">124000</ecte:DeferredRevenueUnrecognized>
    <ecte:SharesOfCommonStockIssuedUponExerciseOfWarrants contextRef="From2012-01-01to2012-06-30" unitRef="Shares" decimals="INF">118500</ecte:SharesOfCommonStockIssuedUponExerciseOfWarrants>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2011-09-30" unitRef="USD" decimals="0">400000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LitigationReserve contextRef="AsOf2011-12-20" unitRef="USD" decimals="0">290000</us-gaap:LitigationReserve>
    <us-gaap:SettlementLiabilitiesCurrent contextRef="AsOf2011-12-20" unitRef="USD" decimals="0">125000</us-gaap:SettlementLiabilitiesCurrent>
    <ecte:SharesOfRestrictedCommonStock1 contextRef="AsOf2011-12-20" unitRef="Shares" decimals="INF">100000</ecte:SharesOfRestrictedCommonStock1>
    <ecte:CompanyLeases contextRef="AsOf2012-06-30_ManufacturinglaboratoryandofficespaceMember" unitRef="Area" decimals="INF">13000</ecte:CompanyLeases>
    <ecte:CompanyLeases contextRef="AsOf2012-06-30_CorporateofficespaceMember" unitRef="Area" decimals="INF">5400</ecte:CompanyLeases>
    <ecte:OfficeLeaseExpiryDate contextRef="AsOf2012-06-30_ManufacturinglaboratoryandofficespaceMember">2014-03-31</ecte:OfficeLeaseExpiryDate>
    <ecte:OfficeLeaseExpiryDate contextRef="AsOf2012-06-30_CorporateofficespaceMember">2014-04-30</ecte:OfficeLeaseExpiryDate>
    <ecte:OfficeLeaseExpiryDate contextRef="AsOf2012-06-30_ManufacturinglaboratoryandofficespacemMember">2017-10-31</ecte:OfficeLeaseExpiryDate>
    <ecte:OfficeLeaseExpiryDate contextRef="AsOf2017-05-31_CorporateofficespaceMember">2017-05-31</ecte:OfficeLeaseExpiryDate>
    <ecte:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2012-01-01to2012-06-30" unitRef="Shares" decimals="INF">28666</ecte:StockIssuedDuringPeriodSharesIssuedForServices>
    <ecte:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2011-01-01to2011-06-30" unitRef="Shares" decimals="INF">100000</ecte:StockIssuedDuringPeriodSharesIssuedForServices>
    <ecte:StockIssuedDuringPeriodSharesIssuedForServicesValue contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">50299</ecte:StockIssuedDuringPeriodSharesIssuedForServicesValue>
    <ecte:StockIssuedDuringPeriodSharesIssuedForServicesValue contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">339000</ecte:StockIssuedDuringPeriodSharesIssuedForServicesValue>
    <ecte:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum contextRef="From2011-01-01to2011-06-30">P6Y</ecte:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum>
    <ecte:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm2Maximum contextRef="From2012-01-01to2012-06-30">P6Y6M</ecte:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm2Maximum>
    <ecte:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm2Maximum contextRef="From2011-01-01to2011-06-30">P6Y6M</ecte:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm2Maximum>
    <ecte:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2012-01-01to2012-06-30" unitRef="Shares" decimals="INF">1.84</ecte:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2012-01-01to2012-06-30" unitRef="USDPShares" decimals="INF">4.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <ecte:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3 contextRef="AsOf2012-06-30">P6Y1M6D</ecte:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3>
    <ecte:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3 contextRef="AsOf2011-12-31">P7Y3M18D</ecte:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3>
    <ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsMadeInPriorPeriodWeightedAverageGrantDateFairValue contextRef="From2012-01-01to2012-06-30" unitRef="USDPShares" decimals="INF">0.92</ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsMadeInPriorPeriodWeightedAverageGrantDateFairValue>
    <ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="From2012-01-01to2012-06-30" unitRef="USDPShares" xsi:nil="true" />
    <ecte:LineOfCreditFacilityPrincipalPayment contextRef="From2012-01-01to2012-06-30_NonRevolvingDrawCreditFacilityMember" unitRef="USD" decimals="0">5000000</ecte:LineOfCreditFacilityPrincipalPayment>
    <ecte:TermOfCreditFacility2 contextRef="From2012-01-01to2012-06-30_NonRevolvingDrawCreditFacilityMember">P5Y</ecte:TermOfCreditFacility2>
    <ecte:DrawCreditMaximumAmountAvailableAdditionalIncrease2 contextRef="From2012-01-01to2012-06-30_NonRevolvingDrawCreditFacilityMember" unitRef="USD" decimals="0">3000000</ecte:DrawCreditMaximumAmountAvailableAdditionalIncrease2>
    <ecte:IncrementInAmountMaximum1 contextRef="From2012-01-01to2012-06-30_NonRevolvingDrawCreditFacilityMember" unitRef="USD" decimals="0">20000000</ecte:IncrementInAmountMaximum1>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod contextRef="From2012-01-01to2012-06-30_NonRevolvingDrawCreditFacilityMember" unitRef="Percent" decimals="INF">0.10</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <ecte:InvestmentWarrantsExercisePrice contextRef="From2012-01-01to2012-06-30_NonRevolvingDrawCreditFacilityMember" unitRef="USDPShares" decimals="INF">2.0</ecte:InvestmentWarrantsExercisePrice>
    <us-gaap:SubsequentEventDescription contextRef="From2012-01-01to2012-06-30_NonRevolvingDrawCreditFacilityMember">In addition, for each $1,000,000 draw, the Company will issue Montaur a warrant to purchase 1,000,000 shares of Common Stock, with a term of five years and an exercise price equal to the lesser of: (a) 150% of the market price of the Common Stock at the time of the draw (but in no event less than $2.00 per share), or (b) $4.00 per share.</us-gaap:SubsequentEventDescription>
    <ecte:CompanysFacilitiesLeaseExpense1 contextRef="From2012-01-01to2012-06-30" unitRef="USD" decimals="0">74000</ecte:CompanysFacilitiesLeaseExpense1>
    <ecte:CompanysFacilitiesLeaseExpense1 contextRef="From2011-01-01to2011-06-30" unitRef="USD" decimals="0">86000</ecte:CompanysFacilitiesLeaseExpense1>
    <ecte:CompanysFacilitiesLeaseExpense1 contextRef="From2011-04-01to2011-06-30" unitRef="USD" decimals="0">53000</ecte:CompanysFacilitiesLeaseExpense1>
    <ecte:CommonStockSharesOutstanding1 contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">38836022</ecte:CommonStockSharesOutstanding1>
    <ecte:CommonStockSharesOutstanding1 contextRef="AsOf2012-06-30_Plan2003Member" unitRef="Shares" decimals="INF">514000</ecte:CommonStockSharesOutstanding1>
    <ecte:WarrantsExpirationPeriod contextRef="AsOf2012-06-30_WeightedaveragetimetoexpirationinyearsMember">P11M1D</ecte:WarrantsExpirationPeriod>
    <ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1 contextRef="AsOf2012-06-30" unitRef="Shares" decimals="INF">1334844</ecte:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1>
    <ecte:IssuanceOfWarrantsToPurchaseCommonStock contextRef="From2012-01-01to2012-06-30_NonRevolvingDrawCreditFacilityMember" unitRef="USD" decimals="0">4000000</ecte:IssuanceOfWarrantsToPurchaseCommonStock>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoplacementagentsinprivateplacement1Member">2015-02-09</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtofinancialinvestmentadvisor1Member">2013-02-10</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtofinancialinvestmentadvisor2Member">2013-03-03</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement1Member">2014-06-30</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement2Member">2014-11-13</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacementofpreferredstock1Member">2013-09-30</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacementofpreferredstock2Member">2013-10-28</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacementofpreferredstock3Member">2014-02-28</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtovendor1Member">2014-03-15</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement3Member">2014-11-13</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtovendor2Member">2012-12-01</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement4Member">2014-12-03</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement5Member">2015-02-09</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoinvestorinprivateplacement6Member">2015-03-18</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement7Member">2012-11-05</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement8Member">2012-11-05</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement2Member">2012-11-05</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement3Member">2012-11-05</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement9Member">2012-11-26</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement10Member">2012-11-26</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement11Member">2012-12-29</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement12Member">2012-12-29</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement4Member">2012-12-29</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement5Member">2012-12-29</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement13Member">2013-01-04</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement14Member">2013-01-04</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement6Member">2013-01-04</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement7Member">2013-01-04</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement15Member">2013-02-03</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement16Member">2013-02-03</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement8Member">2013-02-03</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoplacementagentinprivateplacement9Member">2013-02-03</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement17Member">2013-02-08</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement18Member">2013-02-08</ecte:InvestmentWarrantsExpirationDate>
    <ecte:InvestmentWarrantsExpirationDate contextRef="AsOf2012-06-30_Grantedtoinvestorsinprivateplacement19Member">2014-12-07</ecte:InvestmentWarrantsExpirationDate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2012-04-01to2012-06-30">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 9pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 10pt; font-weight: bold; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Stock Option Plans&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 10pt; font-weight: bold; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2003 Plan&lt;/td&gt;&lt;td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2008 Plan&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid"&gt;Shares Available For Issuance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="width: 56%; text-align: justify; text-indent: -7.9pt; padding-left: 7.9pt"&gt;Total reserved for stock options and restricted stock&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1,600,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;10,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Net restricted stock issued net of cancellations&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(161,250&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,208,406&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Stock options granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,544,491&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,275,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Add back options cancelled before exercise&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;678,491&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;375,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Options cancelled by plan vote&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Remaining shares available for future grants&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;572,750&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,891,594&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 9pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"&gt;Not Pursuant to a Plan&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;Total granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;1,544,491&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;2,275,000&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;3,100,000&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Less:&amp;#160; Restricted stock cancelled&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#151;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 46%; text-align: justify; text-indent: 22.5pt; padding-left: 5.4pt"&gt;Options cancelled&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(678,491&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(375,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(1,383,334&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: 22.5pt; padding-left: 5.4pt"&gt;Options exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(352,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(130,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(666,666&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Net shares outstanding before restricted stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;514,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,770,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,050,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,255,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Net restricted stock issued net of cancellations&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;161,250&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,208,406&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;284,844&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Outstanding shares at March 31, 2012&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;675,250&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,978,406&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,334,844&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
</xbrli:xbrl>
